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Abstract 
In recent years there has been an increased drive towards point of care testing (POCT), in 
which assays are performed at the site of the patient. This has many benefits, critically; the 
time for a result to be obtained will be significantly reduced, allowing for greater and more 
effective decision making. Many currently used bioassay methods are not affordable in 
resource poor areas where infectious disease is most prevalent, in order to combat this issue 
many research groups are attempting to miniaturise equipment for portability and make 
assays more affordable and therefore more accessible. With the aims of generating a new 
assay platform which is highly portable and affordable, the work in this thesis presents the 
development of several generic methods utilising nano- and micro-scale beads coated with 
aptamer which are then monitored interacting with target proteins with Tunable Resistive 
Pulse Sensing (TRPS). 
Aptamers are short oligonucleotide sequences which are capable of binding to a wide range 
of targets with high selectivity and comparable affinity to antibodies while possessing greater 
stability and have begun to challenge the role of antibodies. When aptamers bind a target, 
they often undergo a conformational change. In the assays described herein, this 
conformational change is key to the observed signal changes. TRPS is a pore-based system in 
which beads moving through a pore cause a measurable increase in resistance which can be 
used to derive particle size, concentration, and mobility. 
During the course of this thesis several template TRPS aptasensors have been developed. 
TRPS was successfully used to confirm the successful coating of nano- and micro-scale 
beads with DNA aptamers by monitoring an increase in electrophoretic mobility when the 
negatively charged DNA is added to the surface. Following on from this, TRPS was used to 
monitor the interaction of aptamer tagged beads with thrombin protein enabling thrombin 
detection down to 1.4 nM and the comparison of several thrombin-aptamers with results 
comparable to previously published SPR data. Thrombin was postulated to shield the 
negative DNA, resulting in a decrease in mobility, and the magnitude of this charge shielding 
was found to depend upon the binding mechanism of the aptamer used. This effect is not 
thought to be specific to our system nor to thrombin, the principles outlined here may be 
applied to other RPS technologies, or by interchanging of the aptamer, different proteins. In 
later chapters, this method is expanded to include multiplexed detection of growth factors and 
a significant improvement in signal. 
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Following on from this, the controlled aggregation of avidin coated beads in the presence of 
biotinylated-BSA was explored. Factors impacting upon this assay were discussed including 
magnetic separation, particle size and particle concentration, and different methods of data 
interpretation were presented. This aggregation study identified several key parameters in the 
use of TRPS in aggregation assays. Using the methods outlined by the study of aggregates, a 
dispersion assay was then designed in which the interaction of thrombin proteins with 
clusters of particles brought about the release of many small particles by the disruption of 
double stranded DNA linkages. This dispersion assay incorporated magnetic separation to 
simplify the read-out and relied on measuring particle concentration rather than mobility, 
enabling the use of additional pressure to increase speed and ease of use. Using this method, 
thrombin was able to be detected down to 100 fM, a significant advancement in TRPS 
aptasensors.  
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1.1. Biomarkers and bioassays 
A biomarker is defined as “a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacological responses 
to a therapeutic intervention” 1. The measurement of biomarkers can therefore provide 
information for diagnoses, as well as for the improvement of treatment strategies hence, there 
is great demand for new assay techniques2–4. 
Bioassays are used to quantify the abundance or activity of a biomarker, for example proteins 
expressed in disease states5. In order to improve healthcare for all, including those in 
resource-poor areas, it is desirable for new bioassays to be developed which are affordable, 
easy to use, and highly portable
6
. In addition to considerations of cost and portability there is 
a drive to reduce bioassay time and move toward point-of-care testing7.  
Due to the complexity of biological processes one biomarker measured in isolation could be 
attributed to many diseases, therefore to provide greater confidence in diagnoses it is 
advantageous to be able to detect multiple biomarkers simultaneously. Monitoring 
biomarkers increases the ability to personalise medicine based on individual differences and 
disease subtype; off-target effects are then reduced and treatment is more effective. Being 
able to perform multiple measurements simultaneously would reduce total assay time and 
negate the need for repeated testing. Many current gold standard bioassays such as Enzyme 
Linked Immunosorbent Assays (ELISAs) and Polymerase Chain Reaction (PCR) often 
require large equipment and are labour intensive, requiring skilled technicians to perform. 
Many new technologies have emerged to address the demand for sensitive, rapid, portable, 
and inexpensive tests. 
With the miniaturisation of equipment and greater precision in electronics it is possible to 
generate smaller devices, with instruments that would have at once occupied a whole lab now 
able to be carried
8
. Some of the most successful point-of-care tests can easily fit in a pocket 
and be used at home by the individual, these include lateral flow tests (e.g. home pregnancy 
testing)
9,10
 and electrochemical sensors (e.g. hand-held glucometers for the monitoring of 
blood glucose)
11
. Several groups have adapted these popular and readily available tests to be 
the transducer for the detection of a wide range of analytes including food contaminants
12,13
 
and infectious agents
14,15
. 
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1.2. Bead based bioassays 
Several recently developed bioassays employ the use of nano and microscale synthetic beads, 
sometimes known as nano or microparticles16. The size of bead chosen largely depends on the 
desired detection method and the resolution of the technology used to read a signal. In order 
for these nanoparticles to be of use in bioassays they must be functionalised with a molecule 
to recognise the desired target. Nanoparticles can be conjugated to aptamers and antibodies to 
bind to the target, and/or to fluorophores to aid detection and are now routinely characterised 
by light scattering
20
, fluorescence
9,12,23
, colourimetry
17–19
 and flow cytometry
24,25
.  
A problem in bioassays can be the low signal-to-noise ratio and significant non-specific 
adsorption due to the complexity of the media analysed (e.g. serum), to overcome some of 
these issues superparamagnetic (SPM) particles are being incorporated into assays. Suitably 
small ferro- and ferrimagnetic nanoparticles are capable of a phenomenon known as 
superparamagnetism 
20,21
, these particles hold no permanent dipole and in the presence of an 
external magnetic field their magnetic moments align leading to magnetisation, which is then 
abolished on the removal of the field. SPM particles have been proven to be useful in sample 
preparation to aid washing and remove unwanted entities without the need for complicated or 
expensive equipment
21,22
. SPM allows the particles to be separated, washed and pre-
concentrated in electrolyte buffer without affecting the subsequent measurements with only a 
handheld magnet, unlike more aggressive methods such as centrifugation which may damage 
the sample. SPM particles have been incorporated into a variety of both diagnostic and 
therapeutic interventions
20,21
. SPM particles have been used as contrast agents in Magnetic 
Resonance Imaging (MRI)
23,24
, for the measurement of disease biomarkers through Surface 
Plasmon Resonance (SPR)
25
, and for the targeted delivery of drugs
24,26
.  
Magnetic bead based bioassays have also been developed around controlled aggregation of 
particles upon the introduction of the target. When the target contains multiple binding sites it 
is possible for one target molecule to interact with multiple beads simultaneously, leading to 
the formation of aggregates
27–31
. In these assays the concentration of the target is related to 
changes in the aggregate size or frequency
32
. The use of aggregates allows for a simple and 
label-free detection approach and has been used with gold particles
19,33
, fluorescence, or 
fluorescence resonance energy transfer
34
 often in conjunction with optical, cytometry
35
, 
magneto resistive sensing
36
, and dynamic light scattering detection platforms
28,37
. Alternative 
detection strategies for monitoring aggregation using superparamagnetic beads (SPBs) have 
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relied upon light scattering techniques to monitor the size of the aggregates using chain 
length
37
 or turbidity
28,36
 and changes in magnetic properties as particles are forced to be in 
close proximity to each other
31
. These technologies have been demonstrated with detection 
levels down to picomolar levels, with assay times as low as 5 minutes, however light 
scattering and optical techniques can have a limited dynamic range and could prove difficult 
to multiplex
38
 as it would not be possible to separate the signals. 
1.3. Aptamers 
A key component of many biosensors is the analyte recognition. The ability to selectively 
capture one analyte amongst contaminants provides specificity in the sensor. Traditionally, 
this is done using antibodies. Antibodies are glycoproteins secreted by the immune system to 
detect and bind to foreign bodies by recognition of antigens on the target
39
. Each antibody 
binds to a specific epitope of the target antigen to disarm the potential hazard and signal other 
immunological cells to destroy it. Since their discovery, antibodies have been used 
extensively in both research and clinical settings commonly combined with fluorophores or 
enzymes to allow detection
40
.  
Raising antibodies to an analyte is a process both lengthy and expensive, requiring the use of 
animals and/or cell cultures and with no guarantee of success. Once antibodies have been 
generated their shelf-life is quite limited and they require careful handling to preserve 
activity. In addition, methods using antibodies are in themselves inherently difficult 
processes
41
. An alternative available capture probe with comparative properties are known as 
aptamers. 
Aptamers are short single-stranded oligonucleotide sequences that recognise and bind to a 
wide range of specific targets of interest with high specificity due to their ability to form 
specific 3D shapes42. Aptamers have a longer shelf life than antibodies and unlike antibodies 
do not require the use of animals or cell culture. Aptamer generation is performed from a 
large pool of random oligonucleotide sequences (DNA, RNA or xenonucleic acid - XNA) 
which then undergoes a series of cycles of forced evolution in Systematic Evolution of 
Ligands by Exponential Enrichment (SELEX) which comprises around 6 – 20 rounds of 
binding, partition, elution, amplification and screening, conditioning and mutation as 
displayed in Figure 1.1A 43,44. SELEX, while the method of choice for aptamer generation, 
carries several limitations. The number of rounds, PCR and synthesis increases the time and 
cost of the SELEX process; additionally sequencing and analysing the selected aptamers adds 
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time. SELEX which occurs in solution may also generate aptamers which will behave 
differently when anchored to a surface, such as a bead.  
 
 
Figure 1. 1: Comparison of the aptamer generation methods SELEX (A) and CLADE (B). 
Alternatively aptamers may be developed by a more recent adaptation known as Closed Loop 
Aptameric Directed Evolution (CLADE) 45–47 in which sequences are selected and mutated in 
silico prior to testing in vitro allowing for significant reduction in cost and time for each 
generated aptamer in addition sequences and their location are known throughout the process 
eliminating the need to perform polymerase chain reaction (PCR), as shown in Figure 1.1B. 
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Once aptamer sequences have been generated and are known they are able to be synthesised 
with relative ease and at low cost by any laboratory offering oligonucleotide synthesis 
however it is worth bearing in mind that although many sequences are available through 
primary research papers and online libraries, some sequences are protected by the creators 
and their use restricted.  
New classes of aptamers are emerging with improved affinities and physical properties, for 
example Slow Off-rate Modified aptamers (SOMAmers)
48,49
 to alter affinity, thiolated 
backbones
50
 or speigelmers
51
. Speigelmers are built from artificial nucleotides that are a 
mirror-image of their naturally occurring counterparts, making them resistant to degradation 
by nucleases; due to their increased resistance to degradation and renal clearance speigelmers 
are being investigated as potential drug molecules. 
1.3.1. Aptasensors 
Since their discovery in 1990 aptamers have been increasingly integrated into both existing 
and emerging sensor platforms covered by the umbrella term “aptasensors” 52–54.  Aptamers 
can easily be modified and conjugated to other molecules with reliable immobilisation, 
making them ideal for incorporation into sensor devices. Many aptasensors rely on optical 
detection mechanisms such as fluorescence52,55,56, and there have been many variations upon 
this method using fluorescent dyes
57–60
 and by using nucleotides with fluorescent properties
61
. 
Adding a large molecule such as a dye to an aptamer can impact upon its primary purpose: 
binding
62
. Rather than using an additional dye, the incorporation of fluorescent nucleotides 
into the aptamer the interaction between the aptamer and target molecule has been shown not 
to be compromised and the effects of photobleaching are reduced
63
. These techniques have 
been used to generate assays using single reporters in which a fluorescent dye was affixed to 
the target via an aptamer or using multiple reporters such as combinations of fluorophores 
and quenchers to generate off/on signals specifically in the presence of an analyte
17,55,60
. An 
alternative to the use of fluorophores is a material known as quantum dots, which have far 
improved stability and narrower emission spectra compared to traditional fluorescent dyes 
allowing greater multiplexing power of optical techniques
64,65
. A draw back with fluorescing 
molecules is that detection and quantification require expensive equipment. A far simpler 
type of optical aptasensor utilises gold nanoparticles of which the aggregation or dispersion 
provides a clear colour change which is can be visualised with the naked eye
66,67
, though this 
kind of measurement is not ideal as it is subjective.  
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Aptamers have also been integrated into existing techniques, such as Surface Plasmon 
Resonance (SPR)
68
 and the Enzyme-Linked Immunosorbant Assay (ELISA)
69
 which would 
usually incorporate two antibodies that sandwich a target with one to capture and one to 
detect. The Enzyme Linked Oligonucleotide Assay (ELONA) replaces one or both of these 
antibody elements with an aptamer sequence
54
. With the use of aptamers, pre-existing gold 
standard techniques are able to be improved considerably by decreasing cost, increasing 
stability, and also ease of use by the use of aptamers which are a more robust substrate to 
handle
69
. In addition, the ease of aptamer modification strategies enables the researcher to 
adapt the binding and signal generation with greater ease than in the same techniques 
employing antibodies.  
Many aptasensors to date have been developed with the aim of being used in clinical 
measurements, as such comparison between these techniques is important so that the most 
reliable and valid aptasensor is chosen. Hence, commonly used targets include thrombin
45,70
, 
Platelet Derived Growth Factor (PDGF)
19,71
, IgE
72
 and ATP
73,74
 as these aptamer sequences 
are well established and characterised. By using these molecules as standards it is possible to 
compare emerging and existing techniques. Aside from proof-of-concept works aptasensors 
have been developed against high profile targets such as cancer biomarkers
75,76
, HIV
77
 and 
cocaine
55
 as well as the detection of microbes
78
. 
1.4. Particle characterisation 
For many years the gold standard of particle characterisation in terms of accuracy has been 
microscopy. Scanning and Transmission Electron Microscopy (SEM and TEM) direct an 
electron beam at a specimen and detect the electrons scattered or occluded by the sample
79,80
. 
Both SEM and TEM can detect a reported size range of 50 nm – 100 µm with a high level of 
accuracy
81
 and can provide qualitative information regarding the visual characteristics of a 
sample. These methods have severely limited concentration determination and are further 
limited because only particles in the field of view can be measured requiring the sample to be 
very evenly dispersed. Furthermore, SEM and TEM cannot provide ζ-potential analysis or 
surface chemistry analysis. 
In terms of a POCT device, SEM and TEM techniques are labour intensive and require very 
highly trained microscopy operatives to use. Additional factors preventing the use of SEM 
and TEM becoming widely used POCT devices are that the equipment is very large and 
expensive, there is low throughput and the particles cannot be analysed in situ
81
. 
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One microscopy-based commercial platform available for particle characterisation is the 
NanoSight, a schematic for which is shown in figure 1.2, which attempts to use the precision 
of microscopy while reducing labour intensity. NanoSight combines microscopy and light 
scattering techniques to provide in situ analyses of nanoparticle movement in tandem with 
Nanoparticle Tracking Analysis Software (NTA). The NanoSight is able to provide both 
qualitative and quantitative information regarding the size, concentration, zeta-potential (ζ) 
and aggregation using Brownian motion
82
. The NanoSight is able to detect fluorescence and 
can utilise video for time-course experiments.  
An advantage of the NanoSight over traditional light scattering techniques is the ability to 
observe polydisperse samples rather than providing an average reading for all the particles in 
the sample; however, light scattered by larger particles are sometimes able to occlude smaller 
particles behind them
38,83
. 
Dynamic light scattering (DLS) techniques focus light into a sample and detect photons 
scattered by particles in dispersion and uses Brownian motion to correlate information 
regarding average particle size and zeta-potential (ζ) in the colloidal dispersion84, however 
concentration analysis is not possible
83
. One of the advantages of DLS is that it is quick, 
generating results in 5 - 10 minutes, and requires a relatively small amount of retrievable 
sample (~ 1 mL), furthermore the software and instrument are user-friendly; nevertheless 
there are several limitations which should be considered when using DLS. 
Figure 1. 1: Schematic displaying the NanoSight set up. 
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DLS provides an average of all the particles which are measured simultaneously; smaller 
particles can be hidden behind the scattered light from larger particles and the end results can 
be significantly biased by the presence of small populations of large particles or aggregates, 
as such, DLS is not suitable for polydisperse samples. Another common problem encountered 
by DLS users is that larger particles (larger than 1 µm in diameter) can settle to the bottom of 
the cuvette
82
.  
Flow cytometry is a very high-throughput method of detecting scattered light/fluorescence of 
particles as they pass through the flow cell and are exposed to a laser light source, see figure 
1.3 for schematic of a basic set up. Developed in the early 1970s for analysis of blood 
samples, flow cytometry is able to conduct particle-by-particle analysis on particles between 
500 nm and 40 µm in diameter. Flow cytometry is able to provide relative concentration and 
size analysis using only 500 µL of sample. The detected optical signal is processed by 
specialised hardware and received by a computer containing software to receive and store 
data
85,86
. 
 
Figure 1. 2: Illustration of a general flow cytometry set-up. 
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By quantification of the structural features of each entity (cells, organelles, nanoparticles et 
cetera) which pass through the flow cell it is possible to distinguish and sort through many 
different cell types within one mixture, in addition fluorescence intensity is measured at 
several different wavelengths so that the quantities of specific components can be determined 
at once
86
. 
Flow cytometry has been used extensively since its development for many different 
biomedical applications including analysis of cell cycles, protein expression, and diagnostics. 
Some major diagnostic applications of flow cytometry are surface analysis of cancers, 
detection of HIV
87
, and whole red blood cell analysis (malaria, sickle cell anaemia); however 
it has yet to really emerge as a POC device. One reason for this may be the large size and 
expense of the flow cytometer and servicing. Several laboratories have attempted to 
miniaturise flow cytometers and reduce their overall cost by using microfluidics
88
, however 
this is made problematic as the components required for cell flow, excitation and detection 
are traditionally bulky and their alignment is critical. Additionally, the impressive throughput 
seen in conventional flow cytometers is somewhat compromised as the volume of 
interrogated sample is reduced, Di Carlo’s research group at UCLA have attempted to rectify 
this by parallelisation
88
. 
Luminex is a Texas-based biotechnology company which has developed several multiplexed 
bead-based assays and instrumentation for the detection of target analytes building upon flow 
cytometry
64
. Colour-coded microbeads pass through a laser and their emitted wavelengths are 
measured; the microbeads are permeated with dye mixture and used as an individual label for 
different assays enabling vast multiplexing
89
.  
In order to overcome several limitations of optical sensors, pore-based devices based on the 
Coulter Principle are being developed. 
1.5. Pore-based sensors 
An emerging technology platform that is increasingly being used for biosensing is based on 
the Coulter Principle. The Coulter Principle allows analytes suspended in any conducting 
liquid to be characterised by detecting disturbances in an electric field as they pass through an 
opening in a non-conductive membrane. In brief, Coulter counters comprise two fluid filled 
chambers with an electrode in each which are separated by a single pore, as illustrated in 
Figure 1.4A, as objects move through the pore, the movement of ions is blocked resulting in a 
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transient decrease in current, known as the “resistive pulse”90 illustrated in Figure 1.4B. 
Wallace Coulter identified several parameters for utilisation of this phenomenon including 
the requirement for conducting fluid and constraint of the electrical field so that noticeable, 
recordable changes in current occur with particle movement
91
. Originally developed for 
counting biological cells, the measurement of synthetic nanoparticles was first reported by 
DeBlois and Bean in the 1970s, outlining several factors which should be considered when 
conducting an experiment
92
. Recently there has been an increase in interest in the use of 
Coulter counters for characterisation of colloidal particles, DNA and proteins
93
. Technologies 
based on the Coulter principle are collectively known as Resistive Pulse Sensing (RPS) 
although they have also been known as stochastic sensing and Scanning Ion Occlusion 
Sensing (SIOS). 
 
 
Figure 1. 4: A illustration of a generic RPS set up and B an example resistive pulse; a drop in current is 
observed whenever an object moves through the pore, the magnitude reflects the size of the object while 
the duration represents how long it takes the object to move through the pore. 
The types of analyte able to be studied with RPS technology is limited by the availability of 
suitable pores with an appropriate size range for the analyte of interest. Since resurgence of 
the Coulter-counter in the mid-90s many different nanopores, in conjunction with RPS, have 
been explored. These include both biological and synthetic pores.  
Perhaps one of the most utilised biological pores is α-haemolysin, first used in 1996 to detect 
single stranded DNA molecules
94
. α-haemolysin is secreted by staphylococcal bacteria to 
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create pores in phospholipid bilayers (cell membranes)
95,96
, in normal physiology this 
disruption of the cell membrane causes lysis of red blood cells by allowing important 
molecules to uncontrollably flood out of the cell and the increased permeability to water to 
cause cell rupture. Improvements in synthetic biology allow researchers to purposefully 
create pores, using either wild-type or engineered α-haemolysin, in membranes and using a 
patch-clamp monitor changes in ionic current as objects move through the pore for a range of 
applications
97–100
. Since the detection of single-stranded DNA was demonstrated researchers 
have attempted to use RPS sensors to discriminate between different DNA nucleotides
90,91,101
. 
Towards the development of a DNA-sequencing RPS method, Vercoutere et al., were able to 
discriminate different orientations of the terminal nucleotides of 9 base pair hair pins as they 
passed through an α-haemolysin  pore102, however, although current RPS technologies with 
biological pores are able to tell a difference between different known sequences of the same 
length
99
, they lack the spatial and temporal resolution to read DNA base-by-base in a 
sequence
103
. Haemolysin pores have also been used to monitor the translocation of proteins 
under an applied voltage
104,105
, obtain information regarding protein primary structure
98
, the 
detection of metal ions
100
 and other small molecules
106,107
. 
With advancements in fabrication and materials methodology myriad fixed-geometry 
nanopore synthesis techniques have emerged
108,109
.  Synthetic nanopores are easier to 
manufacture at specific sizes and more stable than biological nanopores suspended in 
bilayers
101,108
 making them highly desirable for the development of a more practical sensing 
device
110
. Nanopores are able to be synthesised with a range of techniques to give different 
features and many solid-state nanopores are now available including carbon nanotubes, 
nanopipettes
111,112
, conical
109,110
 or cylindrical pores
113
, and even nanopore arrays for high-
throughput sensing
108
 or multiple pores in series to monitor time-dependent changes
114
. 
Both biological and synthetic “passive” nanopores are able to be modified to provide them 
with specific features to actively encourage specific ligands to enter the pore, for example 
aptamers to capture proteins
105
, disaccharide ligands to explore multivalency
115
 and the 
immobilisation of specific receptors within a nanopore
116
. 
One limitation of solid-state and biological pores is their fixed size which reduces the range 
of analytes able to pass through the pore and can result in irreversible blockages, requiring 
preparation of a new pore altogether. An alternative to solid-state nanopores, size-tunable 
pores have been developed which are able to be manipulated in real-time by stretching and 
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relaxing the pore
91
. Tunable pores are created by mechanically puncturing a thermoplastic 
polyurethane membrane
117
 and their use in RPS technologies is currently termed Tunable 
Resistive Pulse Sensing (TRPS). TRPS is more versatile than solid-state RPS but there are 
limitations to how much each pore can be stretched or relaxed therefore pores are produced 
with differing optimal size ranges which determine the size of analyte able to be measured.  
The iZON qNano is a Coulter-counter based device which can be used to derive information 
regarding particle size and the particle rate can be used to provide an estimate of particle 
concentration
118
, recently, the qNano software has been updated to include facilities for 
measuring zeta-potential (ζ)119,120; these measurements can all be made simultaneously.  
TRPS has been used for a wide range of applications including the measurement of whole 
cells such as bacteria
121
 and viruses
122
, vesicle characterisation
123,124
, aptamer-based 
bioassays
29
 and the investigation of colloidal dispersions including oil-in-water emulsions
125
 
and nano/micro-scale beads
119,126,127
.   
Yu et al., applied TRPS to the measurement of bacterial growth of two strains of bacteria
121
, 
due to the particle-by-particle analysis available with TRPS it is possible to directly count the 
number of cells in solution and the ability to perform real-time analysis allowed the direct 
measurement of bacterial growth. The concentrations found via TRPS were more similar to 
cell counts than OD measurements, suggesting a greater degree of accuracy
121
. This study 
demonstrated the use of TRPS to obtain bacterial cell counts within a matter of minutes, 
which represents an improvement on the plate counting method which is time-consuming and 
shows large variance between laboratories
128
 and with greater accuracy than optical density 
(OD) measurements
121
.  
In addition to the measurement of large cells, such as bacteria, TRPS has also been applied to 
the quantification of much smaller viruses. While the ability to detect particles below a 
diameter of 100 nm is often problematic for many platforms, using TRPS Vogel et al., 
measured and sized adenoviruses with a diameter of 95 nm with a high level of 
reproducibility
127
 and in a more recent work was able to characterise a multidispersed 
bacillovirus-containing pesticide with a range of 200 nm – 2 µm122.  
TRPS has also been applied to the study of microvesicles (MVs). MV is an umbrella term for 
membrane particles created by budding from the phospholipid bilayer of cells under 
physiological and pathophysiological conditions. Originally these were seen as an artefact of 
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biology, however research is increasingly demonstrating that MVs may be an important part 
of cell signalling cascades and cellular exchange and could therefore provide new 
biomarkers
129–132
. MVs range in size from around 20 nm to 5 µm, currently there is no gold 
standard for their characterisation
133,134
 and instrument-instrument variation is large due to 
the individual working ranges of each instrument
135
. While microscopy techniques such as 
SEM and TEM offer great accuracy in sizing MVs, they are limited in their use for 
concentration determination
81
. As MV concentration has been found to vary in several 
different physiological states such as hypercholesterolaemia
123
, atherosclerosis
136
 and even 
exposure to pollutants
137
 determining concentration is important. Flow cytometry has been 
used for high-throughput analysis of MVs, however the lack of resolution below 200 nm 
means that many subtypes of MV may be unaccounted for, leading to an underestimate in 
true concentration and possibly overlooking key markers
123
. The ability to easily and quickly 
change pores and alter geometry using TRPS offers a significant advantage to the 
characterisation of MVs and the provision of particle-by-particle analysis makes TRPS ideal 
for counting MVs
123,138
 in an unbiased manner despite their polydispersity. In reality it is 
likely that several techniques will need to be incorporated to generate a full picture of an MV 
profile due to the individual strengths and limitations of each technique for example for size 
and concentration determination TRPS has a good level of accuracy, but a separate technique 
would need to be employed to measure the molecular composition of those MVs, such as in 
measuring the concentration of low-density-lipoprotein (LDL) cholesterol which has been 
recently measured by Connolly et al (2014) to be linked to familial hypercholesterolaemia 
and to be a valid marker for apheresis monitoring using TRPS for MV size and concentration 
with flow cytometry to determine MV origin and gas chromatography with flame ionisation 
detection (GC-FID) used to monitor the fatty acid composition of the MVs
123
; this 
multifaceted approach is likely the best way to gain a full view of the vesicles being 
investigated, however the individual techniques used in tandem will need to be guided by the 
goals of research being undertaken and the individual strengths and weaknesses of each 
instrument.  
As well as biological particles, TRPS has been demonstrated to be well suited to the size and 
concentration analysis of synthetic particles of a range of compositions
126,139–141
 as well as the 
measurement of surface charge
120,125
. The interaction of nanoparticles with several analytes 
has also been monitored via TRPS and several bead-based bioassays have recently been 
developed for use in TRPS. Typically, these use beads coated with capture probes, either 
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antibodies or aptamers, which cause a measurable change in the configuration of the beads 
upon ligand binding. Several such assays use aggregation as a signal for ligand binding. 
Ang and Yung developed an assay for rapid detection of single-nucleotide polymorphisms by 
using gold particles coated with a spliced complementary sequence to the desired DNA target 
which causes aggregate formation only in the presence of the correct DNA sequence, giving 
rise to a simple yes/no read out. The use of a size-tunable pore was particularly advantageous 
as the pore stretch could be increased such that only aggregates were visible above the level 
of baseline noise
142
. 
Another TRPS based aggregation assay pioneered the use of ‘nanorods’ to provide a signal in 
response to specific aptamer-analyte interactions. Nanorods are nanoparticles which are 
created by electrodeposition to be cylindrical rather than spherical. Unlike spherical particles, 
where their orientation is unknown as they pass through the pore, because rods can vary in 
two dimensions, both length and diameter, it is possible to elucidated nanorod orientation. In 
addition to this, Platt et al., were able to demonstrate that aggregate formation could be 
controlled by differing the composition of the nanorods such that aggregates could form 
either end-on-end or side-on aggregates. Different aggregate orientations were discriminated 
via TRPS, and this could be tailored such that different ligands produced a different response 
allowing increased multiplexing potential
29
. This assay was found to have a femtomolar limit 
of detection for platelet derived growth factor (PDGF), comparable to the sensitivity of 
ELISAs but with significant gains in speed and simplicity
29
.  
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1.6. Summary 
Currently there is a high demand for new portable, rapid and sensitive bioassay techniques. 
The work outlined in this thesis attempts to create and explore new bioassays using a 
combination of aptamers, synthetic beads, and TRPS to create an “aptaTRPS” sensor. 
Aptamers are short oligonucleotide sequences which are capable of binding to a wide variety 
of analytes with high selectivity and specificity. When aptamers bind a target they often 
undergo a conformational change which has been previously monitored in emerging 
analytical sensors. RPS technologies are small and highly portables devices which do not 
require the use of gas lines and carrier fluids and have already been proven as useful for the 
measurement of a variety of biological and synthetic objects. It is hypothesised that by 
anchoring aptamers to nano or microscale beads TRPS can be used to monitor changes 
arising from aptamer-ligand interaction, forming the basis of this PhD Thesis.   
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2.1. Introduction 
As discussed in Chapter One, the aims of the work detailed in this thesis are to generate and 
explore new bioassay techniques using a combination of aptamers, particles, and tunable 
resistive pulse sensing (TRPS). Chapter two provides an overview of general theory relevant 
to these aims and used across all chapters. Additional detailed theory is included in each 
chapter where relevant.  
2.2. Aptamers 
Aptamers are short lengths of single stranded deoxyribonucleic acid (DNA), ribonucleic acid 
(RNA) or a synthetic alternative known as xenonucleic acid (XNA) which contains the same 
bases but is resistant to polymerase due to a different backbone. The experiments discussed in 
this thesis all utilise DNA aptamers, hence, from this point only DNA aptamers shall be 
discussed in detail. DNA is composed of four nitrogenous bases known as nucleotides. These 
can be divided into the purines adenine (A) and guanine (G), and the pyrimidines thymine (T) 
and cytosine (C). In DNA these are bonded to deoxyribose sugar and phosphate to form a 
unit termed a nucleoside. The nucleoside bases are joined covalently by phosphodiester 
bonds to form long polymer chains
1
.  
In the presence of a specific target these sequences undergo 3D conformational changes to 
cause binding in a lock and key fashion – this is known as induced fit binding2–5. Binding 
between the aptamer and target is dependent on structural compatibility, stacking of aromatic 
rings, hydrogen bond formation, and electrostatic and Van der Waals interactions
6
. For many 
aptamers the highly anionic oligonucleotide backbone interacts with positive residues on 
target proteins and is a strong factor in bringing the aptamer into the proximity of the binding 
site
7
. Because the binding mechanisms of aptamers are specific to each target, only aptamers 
used in the research undertaken will be discussed in detail.  
Since the generation of an anti-thrombin aptamer in 1992
8
, thrombin has been widely utilised 
in aptasensors and its mechanism widely studied
9,10
. The first aptamer to thrombin was 
described by Bock et al., and is 15 base pairs long (termed thrombin-15) with the sequence 
5’-GGT TGG TGT GGT TGG-3’8 which has been adapted several times and used in many 
proof-of-concept aptasensor studies
9,11
. In the presence of thrombin, aptamers containing the 
sequence motif “GGNNGGNGNGGNNGG” (where N represents T or A) undergo a 
conformational change to form a G-quadruplex structure11–13, illustrated in Figure 2. 3, which 
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has been found by circular dichroism spectroscopy to occur only in the presence of thrombin, 
implying that there is involvement of the induced fit binding mechanism
14,15
. 
 
Figure 2. 3: Illustration of an example G-quadruplex structure. 
Aptamers to growth factors have also been generated for both therapeutic and diagnostic 
interests
16
. Vascular endothelial growth factor (VEGF) is one such protein for which 
aptamers have been generated. Aptamer VEa5 (also denoted as aHt
7
 or VEap165
17
 in the 
literature) with the sequence 5’-ATA CCA GTC TAT TCA ATT GGG CCC GTC CGT ATG  
GTG CTG GCC AC-3’ binds to the heparin binding domain of VEGF165 via the formation of 
stem-loop structures and electrostatic interactions
7,17,18
.  In contrast, aptamer V7t1 with the 
sequence 5’-TGT GGG GGT GGA CGG GCC GGG TAG A-3’ has been generated to the 
receptor binding domain of VEGF and is currently thought to bind by the formation of a G-
quadruplex. However, the G-quadruplex formed here is specific to VEGF and does not 
interact with other quadruplex-binding targets, such as thrombin
19
. Platelet derived growth 
factor (PDGF) has also been detected using a high-affinity aptamer with the sequence: 5’ 
CAG GCT ACG GCA CGT AGA GCA TCA CCA TGA TCC TG-3’20–23 which forms a 
secondary structure characterised by three double-stranded DNA hairpins
20,21
. 
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2.3. Particles 
2.3.1. Superparamagnetic particles 
Magnetic nanoparticles can be utilised to separate analytes from solution and perform 
washing or pre-concentration steps, as such it is important to consider their properties. In its 
most basic form, magnetism refers to forces of attraction and repulsion between objects 
produced by electric charge and fundamental magnetic moments of atoms.  However, there 
are in fact several different types of magnetism, some of which will be addressed here. 
Both ferro- and ferri-magnetic materials are capable of becoming permanent magnets in the 
presence of an external magnetic force
24. These materials contain several “domains”, 
separated by thin domain walls
25
. When an external magnetic field is applied to a 
ferromagnetic material, the domains rotate to align in the direction of the magnetic field and 
the material is drawn to the magnet, as demonstrated in Figure 2. 4. In ferrimagnetic 
materials, the magnetic moments of the atoms are opposing; however these opposing 
moments are unequal, allowing for spontaneous magnetisation. According to the Néel theory 
of ferrimagnetism, ferrimagnetism is reported to be a consequence of non-identical magnetic 
substructures within the material and negative interactions between them
26
, as illustrated in 
Figure 2. 4.  
Figure 2. 4: Illustration of ferrimagnetic, ferromagnetic, and superparamagnetic materials and their response to 
an external magnetic field. 
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While ferro- and ferrimagnetic materials would separate from solution by being attracted to a 
magnetic, they are subject to effects of hysteresis
24
 whereby magnetisation is retained. 
Hysteresis is perhaps best described via the hysteresis loop in Figure 2. 5A which shows that 
a ferromagnetic material requires application of a reversed magnetic field, an increase in 
temperature, or a lengthy time period before the material returns to a non-magnetic state. 
Hysteresis is believed to be due to a “pinning” of the domains on defects in the crystal lattice 
structure within the material, preventing the domains from relaxing into a random 
orientation
27,28
 as such they need more energy to overcome the barrier to moment reversal. If 
such materials were used in magnetic separation, this would lead to an inability to redisperse 
the particles unless subjected to an opposing magnetic field or increased temperature – which 
may disturb any target analytes. Hence, in order to use magnetic particles for washing and 
extraction it is important that they return to a non-magnetised, separated state in which they 
do not aggregate together and can be analysed.  
Paramagnetic particles display no hysteresis at room temperature, making them useful 
materials for magnetic separation. By reducing the size of the particles of a ferri- or 
ferromagnetic material  to that of a single domain, typically tens of nanometers
29,30
, they 
become superparamagnetic (SPM) due to the fact that the domains are no longer pinned as 
described above, which can rotate freely to align with an external field and are not pinned on 
crystal lattice defects as there are no domain walls to move
24,30,31
 while displaying both a 
higher magnetic saturation, and a steeper gradient of magnetic susceptibility. As presented in 
the hysteresis curve Figure 2. 5B, SPM particles do not display any hysteresis at room 
temperature
32
. In addition, the energy required for them to lose their magnetism is reduced, 
Figure 2. 5: Example hysteresis loops for a ferromagnetic material (A) and a paramagnetic particle (B) at room 
temperature.  
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allowing the SPM domains to separate at room temperature and rotate back to random 
orientations once the external magnetic field has been removed, as displayed in equations 2. 1 
and 2. 2.  
 𝜏 =  𝜏0exp (
Δ𝐸
𝐾𝐵𝑇
) 2. 1 
   
 Δ𝐸 =  𝐾𝑉 2. 2 
 
Where τ is the relaxation time, ΔE is the energy barrier to moment reversal, KB is 
Boltzmann’s constant, T is temperature, K is the anisotropy energy density and V is the 
volume of the particle. Hence, reducing the volume of the particle reduces the energy barrier 
to moment reversal and for sufficiently small particles ΔE is comparable to KB at room 
temperature and the particles can separate
24
. 
By using SPM particles, it is possible to separate them from solution and remove/replace 
buffer or pre-concentrate a sample and then remove the magnet and allow the particles to 
disperse by Brownian motion. These particles can be tagged with biomolecules that can 
selectively capture chosen targets in solution and confounding proteins can be removed via 
magnetic separation
33,34
.  
The SPM beads used in the experiments in this thesis are composed of a core containing 
many individual single-domain iron oxide particles, as displayed in Figure 2. 6. In the 
presence of an external magnetic field, all of the single SPM domains inside the bead align 
and they are drawn toward the magnet, allowing the SPM beads to precipitate on the side of 
an eppendorf and facilitating wash stages as illustrated in Figure 2. 7. Larger particles contain 
Figure 2. 6: Illustration of an example cross-section for a superparamagnetic bead coated with streptavidin. The 
inner Fe3O4 core is composed of many sub-100 nm individual superparamagnetic particles. 
 31 
 
a greater number of SPM cores therefore move toward the magnet more quickly due to the 
higher iron oxide content compared with smaller particles as expected from equation  
2. 3 below: 
 
Where F is the force on a magnetic particle inside a magnetic field, V is the volume of the 
particle, Δχ is the difference in susceptibility between the particle and surrounding buffer 
solution, µ is the magnetic permeability and B is the magnetic field strength. As such, as 
volume of the magnetic material increases, so does the force acting upon it, leading to a faster 
separation. 
Once the magnet is removed, the atomic moments of the particles rotate into a random 
orientation and the magnetism is lost allowing the beads to disperse by Brownian motion. 
These particles can be modified with capture probes, such as aptamers and antibodies, and 
used to extract targets from solution, as displayed schematically. 
 
 
 
 
 𝐹 =  
𝑉. ∆𝜒
𝜇0
(𝐵. ∇)𝐵 2. 3 
Figure 2. 7: Schematic displaying the operation of magnetic separation. A = SPM particles functionalised with 
capture probes are dispersed into the sample. B = a hand-held magnet is introduced and a pellet forms on the 
side of the container, bringing with it any captured target molecules. C = any fluid is carefully pipetted out and 
discarded (or saved for further analysis). D = particles are then suspended in clean buffer solution prior to 
analysis. 
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2.3.2. Colloidal systems 
The term “colloid” is used to refer to a dispersion of small particles of one material in another 
medium which does not settle under gravity
35
. These systems occur naturally in many 
biological products and can be created synthetically with wide variety in composition. A sol 
suspension is the term for solid particles dispersed in a liquid medium
36
, for example, 
synthetic nano- or microparticles dispersed in an electrolyte buffer as used in the course of 
this thesis. For many applications the stability of colloids is key as either aggregation or 
complete dispersion might be required for differing tasks
36
 and stability over time is often 
highly sought after
37
. A major factor in determining the stability of colloidal systems is the 
electric charge on the particle surfaces
35
; the level of stability is able to be measured via the ζ 
potential.  
The net charge at the particle’s surface affects the distribution of ions in the surrounding 
medium. This results in an increased concentration of counter ions, forming an electrical 
double layer. The structure of the double layer comprises the Stern layer of stationary ions 
and a diffuse layer which is loosely bonded. Within the diffuse layer is a hydrodynamic layer 
known as the slipping plane or plane of shear
35,38
.  
ζ-potential is a function of the surface charge and is used as a measure of the electrokinetic 
potential in colloidal systems. ζ-potential (mV) refers to the potential difference between the 
stationary layer of ions surrounding the particle and the surrounding medium at the point of 
the slipping plane, see Figure 2. 8. If the ζ-potential is high, the repulsive forces between the 
Figure 2. 8: Illustration describing the double layer of a negative particle 
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particles are greater and the colloid is described as highly stable, if the ζ-potential is low the 
particles are likely to form agglomerates (the forces of attraction overcome those of 
repulsion)
38
.  
It is important to consider the effect of the chosen buffer upon the stability and mobility of 
the dispersion. The movement of a solid colloidal particle in a stationary liquid under and 
applied electric field is known as electrophoresis. The electrophoretic mobility, µ, of a colloid 
is related to the ζ potential of the particle36,37 as expressed in the following equations: 
 𝜇 =
𝑞𝐷
𝐾𝐵𝑇
  2. 4 
 𝜁 =
𝜂𝜇
𝜀
 2. 5 
Where q is the effective charge, D is the diffusion coefficient, KB is Boltzmann’s constant, T 
is temperature, η is the viscosity of the buffer solution and 𝜀 is the dielectric constant of the 
solution
39
.  
The charge of the particle is heavily dependent on the composition of the surrounding 
medium, and in buffers close to the isoelectric point (pI) of the particle the colloid loses 
stability and aggregates as the repulsive electrostatic forces between particles is diminished
37
. 
The isoelectric point of an object is the pH at which the particle has no net charge (i.e. it is 
overall neutral because the sum of positively charged species is equal to the sum of 
negatively charge species) due to the reduction or addition of protons. At pH above the pI of 
the particle the net charge is negative, while at pH below the pI have a net positive charge. 
In addition to pH of the buffer it is important to consider ionic strength. Electrophoretic and 
electrostatic behaviour of colloids is largely controlled by the properties of the Stern and 
diffuse layers surrounding the particle
37,40
. The thickness of the diffuse layer is governed by 
the ionic strength of the chosen electrolyte and has a non-zero value that is estimated as the 
inverse value of the Debye parameter, κ, which is provided by the following equation: 
 𝜅 =  𝐹√
2𝐼
ℇ𝑅𝑇
 2. 6 
 
Where F is the Faraday constant, R is the gas constant, and I is the ionic strength
41
. As 
demonstrated by this equation, as ionic strength increases, the thickness of the diffuse layer 
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decreases, reducing drag and increasing mobility
42
. These are important considerations for 
systems where colloid behaviour under an applied electric field is observed and appropriate 
electrolytes must be somewhat carefully chosen.  
2.4. Resistive Pulse Sensing 
Modern Resistive Pulse Sensors (RPS) can be traced back to the Coulter Counter developed 
in the 1950s by Walter H Coulter. These devices are based on the “Coulter Principle” which 
describes the use of an electric field to count particles that are suspended in an electrolyte 
solution
43
. These devices were originally applied to the counting of the rapid and large-scale 
counting of blood cells, a practice which previously required laborious and time-consuming 
manual counting of immobilised cells with microscopy. Since then many different 
adaptations of Coulter counters have been developed with a wide range of targets including 
both synthetic and biological colloids.  
A recent adaption to RPS based on these principles includes the incorporation of a conical 
elastomeric pore which is able to be mechanically stretched or relaxed in real time, this 
adaptation is known as Tunable Resistive Pulse Sensing (TRPS) developed by Izon Science, 
Oxford. The qNano is the commercially available instrument developed by Izon Sciences for 
TRPS and consists of an upper and lower fluid cell, separated by a non-conductive, flexible 
membrane with a singular central pore, and stretching apparatus
39,44,45
. The pores developed 
for use in TRPS are generated by puncturing 200 µm thick thermoplastic polyurethane (TPU) 
membranes with a tungsten needle, giving rise to an approximately conical pore
39,46
.  
The basic operation of RPS devices is as follows: two fluid filled chambers are separated by a 
single pore in a non-conductive membrane. Electrodes in each fluid chamber are used to 
establish a current across the pore. Resistance in a conical pore is determined by the 
conductivity of the electrolyte used and pore dimensions as described by equation 2. 7 
below
39
: 
 𝑅 =  
4𝜌𝐿
𝜋𝐴𝐵
 2. 7 
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Where ρ is the resistivity of the electrolyte, L is pore length, A is the small pore opening 
radius and B is the large pore opening radius. Ohm’s law can then be applied to calculate the 
ionic current, ip, at a given applied potential where V=iR, where R is resistance, providing a 
baseline current. When a particle moves through the pore this results in a local increase in 
resistance resulting in a so-called “resistive pulse” as the current transiently decreases until 
the object has passed through the pore as shown schematically in Figure 2. 9. 
The conical shape of the pores used in TRPS give rise to an asymmetric resistive pulse shape, 
as resistance is highest at the narrowest part of the pore there is a sharp initial decrease in 
current which then tails back toward the initial baseline current as the object moves through 
the widening pore.  
The magnitude of the resistive pulse, Δip, is dependent upon the volume of electrolyte 
displaced by the particle as it moves the pore and can be used to determine the dimensions of 
an object by its individual resistive pulse by the following equation 2. 8
22,47
: 
 
Δ𝑖𝑝
𝑖𝑝
=  
𝑆(𝑑𝑝, 𝑑𝑠)(𝑑𝑠
3)
𝑙𝑝(0.8𝑑𝑝)(𝑑𝑝2)
 2. 8 
 
Where dp is pore diameter, ds is particle diameter, lp is pore length and S(dp,ds) is a correction 
factor that depends on the relative values of both the pore and particle diameters
22
. This 
estimation is applied to cylindrical pores but has been demonstrated to hold a good degree of 
accuracy for attaining particle size using conical pores
44
. As is apparent from equation 2. 8 
the magnitude of the resistive pulse is dependent on the relationship between the dimensions 
of the particle and the pore orifice such that a smaller pore is able to analyse smaller particles. 
Figure 2. 9: (A) schematic representation of a particle traversing the pore opening. (B) Example resistive pulse 
observed with a conical pore annotated with reference to the particle position during the resistive pulse in (A). 
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This is especially important in the context of tunable pores as they are able to be tuned in real 
time to increase or decrease the pulse magnitude so that pulses are visible above the level of 
baseline noise and so that blockages do not occur.  
In addition to finding particle size, TRPS can be used to find particle concentration. Particle 
concentration is related to the frequency of resistive pulses as particles move through the 
pore. Particle velocity (VS) through the pore is determined by the sum of the forces of 
pressure driven flow (VP), electrophoretic mobility of the particle (VEP), electroosmosis (VEO), 
and diffusion effects (VD) as described in equation 2. 9 below
47
:  
 
𝑉𝑠 =  𝑉𝑃 +  𝑉𝐸𝑃 +  𝑉𝐸𝑂 +  𝑉𝐷 
=  
𝑑𝑝
2
32𝜂𝑙𝑝′
Δ𝑃 +  
𝜇
𝑙𝑝′
𝐸 +  
𝜀𝜁𝑝𝑜𝑟𝑒
4𝜋𝜂𝑙𝑝′
𝐸 +  
𝐷𝑆
𝑙𝑝′𝐶
𝐶 
2. 9 
 
Where η is the solution viscosity, lp’ is the length of the pore after a correction factor for end 
effects = lp + 0.8dp, ΔP is the pressure across the pore, µ is the electrophoretic mobility of the 
particle, E is the applied electric field, ε is the solution dielectric constant, ζpore is the zeta 
potential of the pore surface, DS is the diffusion coefficient of the particle, and C is the 
particle concentration
47
.  
If particle concentration is already known using TRPS under fixed conditions it is possible to 
use resistive pulse frequency, J, to elucidate the surface charge of a colloid using the Nernst-
Planck approach in the following equation
48,49
: 
 
𝐽
𝐶
=  𝜀
(𝜁𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 −  𝜁𝑝𝑜𝑟𝑒)
𝜂
𝐸 +  
𝑄𝑝
𝐴
 2. 10 
 
Where Qp is pressure driven flow, and A is the diameter of the narrowest pore constriction. 
As is apparent from equation 2. 10 the ζ-potential (or surface charge) of the particle is a 
factor in determining rate as alterations to zeta potential will subsequently alter the 
electrophoretic mobility of the particles as described earlier in equation 2. 5.  
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2.4.1. Theory of Operation 
The instrument most associated with TRPS is the qNano, manufactured by Izon Sciences, 
Oxford. Similar to standard RPS, two fluid reservoirs are separated by a single pore which 
are filled with a conducting electrolyte buffer. In the qNano, the pore is mounted horizontally 
with reservoirs above and below the pore membrane, as displayed in Figure 2. 10. As stated 
previously, the qNano uses an elastic size-tunable pore which is fabricated in a thermoplastic 
polyurethane (TPU) membrane. The membranes are penetrated with a needle to create a 
single pore which is conically shaped
46
. The size and geometry of the fabricated aperture can 
be modified by modifying the puncturing needle thus allowing the detection of particles 
ranging from 50 nm to 10 μm over the full range of manufactured pores50. The cruciform 
pore is mounted by eyelets to teeth on the instrument, above the lower fluid cell, the system 
can be seen in figure 2.8. The arms can be altered to increase the stretch on the pore, where it 
Figure 2. 10: Schematic showing the setup of the TRPS device. 1 birds-eye view of the lower fluid cell, this 
channel holds 75 – 80 µL of electrolyte buffer and contains an electrode. 2 the pore is mounted laterally to the 
device by eyelets on the pore being hooked to teeth on the instrument – these teeth are able to be moved apart or
closer together, stretching or relaxing the pore respectively. 3 the upper fluid cell is fitted to the instrument 
securely, and a 40 µL sample is pipetted into it. 4 side-view of a particle traversing the conical pore and an 
illustration of the resultant asymmetric current trace. 
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has been shown that applying a stretch of 10 mm to the membrane increases the pore opening 
by 54%
45
. 
The setup of TRPS is relatively simple. Firstly, the pore is attached to the instrument as 
shown in figure 2.8 and the desired pore stretch is applied by separation of the teeth on the 
instrument (>41 mm, 41 being the smallest distance between the teeth applying no stretch to 
the membrane), the electrolyte is then carefully pipetted into the lower fluid cell under the 
pore (75 µl). Care needs to be taken to ensure no bubbles are introduced into the electrolyte, 
if bubbles do occur the electrolyte needs to be replaced. If no bubbles are present, the upper 
fluid cell can be placed on top and twisted into place. The electrolyte solution can then be 
placed into the upper fluid cell (40 µl). A faraday cage is placed over the fluid cell to reduce 
background noise and the system is switched on using the Izon Control Suite software. Upon 
the application of a voltage a stable baseline should be observed. Once a stable baseline is 
apparent, the electrolyte can be removed from the upper fluid cell and a sample introduced. 
Once the sample has been introduced the stretch applied to the pore can be fine-tuned so that 
the blockades produced by the sample are visible above the level of baseline noise. When 
stretch is increased, resistance through the pore decreases, represented by a current increase 
likewise, if the current were to decrease suddenly that may be indicative of a blockage in the 
pore as the pore orifice is occluded.  
Unlike solid state pores where the size of the pore is always known, the tunable pore must 
first be characterised before the size of the analyte can be accurately measured using TRPS. 
This is done using calibration beads of a known size and must be done prior to sample 
analysis and under the same conditions. As stated above in equation 2.8, Δip is proportional to 
the volume of the object moving through the pore, by using a reference sample of known 
diameter beads with narrow size distribution, the Δip of an unknown sample can be calibrated 
with the reference sample to obtain the measured diameter. The same principal can be applied 
to particle concentration whereby a reference sample of known concentration can be 
measured to provide a baseline rate and because rate is proportional to concentration, stated 
in equation 2.9, it is possible to elucidate concentration from the rate of an unknown sample. 
Due to the fact that a number of factors, such as surface charge, can alter particle rate through 
the pore, to attain an accurate calibration it is necessary for a pressure to be applied to 
overcome the forces of electroosmosis and electrophoretic mobility
39,44,45,51
.  
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The amount of pressure applied is based on the variable pressure module (VPM) used in 
conjunction with the Izon qNano. The VPM has a mobile ‘arm’ with a scale of 0-20 pressure 
units. The amount of pressure applied is relative to the length of the arm impacting on the 
system. For example, if the arm is inserted 5 cm into the system, a pressure of ‘5 cmH2O’ is 
applied. For a negative pressure, or vacuum, the length the arm is pulled out is equivalent to 
the magnitude of pressure applied and is denoted as ‘-5 cmH2O’, for example. Each cm of 
pressure is equivalent to approximately 1000 Pa. For greater precision the VPM is also able 
to operate from 0 – 20 mmH2O.  
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Chapter Three 
Attachment of DNA to nanoscale beads and detection 
via TRPS 
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3.1. Abstract: 
In order to create a TRPS-based biosensor, it is first necessary to have reliable methods of 
aptamer immobilisation and a means of detecting when the aptamers have been successfully 
immobilised. As such, the work discussed in this chapter sought to establish a method for the 
confirmation of successful DNA conjugation to the surface of nano- and micro-scale 
synthetic beads using TRPS following either conjugation via biotin-avidin linkage or EDC 
coupling chemistry. When DNA is added to the surface of beads by either method, the 
mobility of the beads increase as their negative surface charge is increased, this is visible as a 
signal in TRPS in both an increase in rate and decrease in Full Width Half Maximum 
(FWHM) representing an increase in mobility. Following confirmation that a detectable 
change in signal is observable when DNA is successfully bound to the beads using TRPS, the 
impact of factors including bead diameter and mass, in addition to DNA length and 
hybridisation of DNA complements on TRPS measurements were explored.  
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3.2. Introduction: 
To develop an aptamer-based biosensor using TRPS it will be necessary to confirm the 
presence of aptamer on the surface of beads. Ideally, this measurement should also be able to 
be performed using TRPS to reduce the need for additional instrumentation, reagents, and 
time. DNA is composed of a negatively charged sugar-phosphate back bone and a 
combination of purine and pyramidine bases. When the negatively charged DNA is attached 
to the surface of the beads, this should lead to an increase in overall surface charge and an 
increase in electrophoretic mobility, visible as an increase in rate as discussed in chapter two 
and described in equation 2.9. 
Two methods for immobilising DNA onto a beads surface have been chosen for 
investigation. First, the use of commercially available streptavidin coated superparamagnetic 
beads (SPBs) was explored. Oligonucleotide sequences are able to be synthesised with 
functional groups at either end; modification with biotin is now routinely offered from many 
custom oligonucleotide services; by fuctionalising one end of the DNA or RNA sequence the 
direction of immobilisation is consistent, in the case of an aptamer this is important to allow 
the binding motif to interact with the target. The streptavidin-biotin complex is the strongest 
known non-covalent interaction with a high affinity (Kd, = 10
-15
 M)
1
 between a protein and a 
ligand. The bond between biotin and avidin is formed rapidly and is robust against pH, 
temperature and solvent exposure. Biotin is a relatively small molecule (244.3 daltons), as 
such it can be conjugated with many molecules without significantly altering biological 
activity. Streptavidin, in particular, is isolated from streptomyces avidinii
2
; this is more 
expensive to produce than avidin itself, but displays a lower degree of non-specific binding 
which is an important consideration in the development of a bioassay. The use of streptavidin 
coated beads and biotin tags, while reliable, does hold several limitations. Beads coated with 
streptavidin are more expensive and are available from fewer suppliers than carboxyl-latex 
beads. In addition, because the attachment of beads to biotinylated DNA is protein based 
there is a reduced shelf life and reduced stability in comparison to the use of carboxyl groups 
and amine modified DNA.  
Secondly, an additional method of conjugating DNA sequences to beads explored was to use 
beads with carboxyl functional groups and amine functionalised aptamer sequences. As such, 
it was necessary to determine the presence of DNA on carboxyl beads which are already 
negatively charged.   
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3.3. Method: 
3.3.1. Chemicals and reagents 
The following chemicals were purchased from Sigma Aldrich, UK, without any further 
purification unless otherwise stated: Phosphate Buffered Saline (PBS – P4417), Tween 20 
(P1379) and MES (2-[N-morpholino]ethane sulphonic acid) hydrate (M2933). EDC (1-ethyl-
3-[3-dimethylaminopropyl]carbodiimide hydrochloride) was purchased from Thermo 
Scientific (22981). Water purified to a resistivity of 18.2 MΩ was used to make all solutions 
unless otherwise specified. 
DNA sequences were purchased as lyophilised powders with HPLC purification, the 
following were sourced from Entelchon, Germany: 5’GGT TGG TGT GGT TGG TTT TTT 
TTT T-Biotin-3’ (Thrombin-15 with 10 T spacer)3 and 5’TGG GAG TAG GTT GGT GTG 
GTT GGG GCT CCC CTT TTT-Biotin-3’ (Thrombin-MArray)4. The sequences 5’ GGT 
TGG TGT GTT TGG TTT TTT TTT T-Amine-3’ (Amine Thrombin 15), 5’GTT TGG TTT 
ATT TTA CTA GTG GCC AGG-Biotin-3’ (ThrombinEvol)5, a random biotin-tagged 
decamer, and 3’CCA ACC ACA CCA ACC 5’ (target) a complementary sequence to 
Thrombin-15 were purchased from Sigma Aldrich’s custom oligonucleotide service. These 
were made up to a stock concentration of 100 pmol/µL. 
Streptavidin modified superparamagnetic beads of 120 nm (Bioadembeads streptavidin plus, 
03211) and 300 nm (Bioadembeads streptavidin, 0.3130) in diameter were purchased from 
Ademtech (France). The following carboxyl beads of known diameter and concentration were 
purchased from Izon Sciences, UK: CPC100B (mode diameter 115 nm, 1 × 10
13
 beads/mL); 
SKP200B (mode diameter 203 nm, 1 × 10
11
 beads/mL); SKP400D (mode diameter 335 nm, 7 
× 10
10
 beads/mL); CPC800C (mode diameter 750 nm, 9.5 × 10
10
 beads/mL). Dynabeads® 
MyOne™ carboxylic acid (650.12) were sourced from Invitrogen Dynal. All beads were 
diluted in 1 × PBST (0.05% tween 20). 
3.3.2. Immobilisation of DNA 
3.3.2.1. Streptavidin coated beads and biotinylated DNA 
The supplied beads were first vortexed and sonicated to ensure monodispersity. 120 nm 
streptavidin coated beads were diluted to a concentration of approximately 3 × 10
9
 beads/mL 
for use as a stock. To 40μL of beads a further 10μL of varied ratios of PBST and aptamer 
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dilutions was added to provide a range of final concentrations from 0.1nM up to 10 000nM of 
DNA. These were vortexed and placed on a rotary wheel for 30 minutes at room temperature 
prior to analysis. 
3.3.2.2. Investigation of DNA hybridisation on the surface of beads 
120nm beads were diluted in PBST to a concentration of 3 × 10
9
 beads/mL to a volume of 2 
mL. From this initial stock 8×200 µL samples were removed to separate clean vials. To each 
a varying amount of biotinylated Thrombin-15 was added to give a concentration range of 10 
nM up to 210 nM, a range guided by the results of the first experiment. These samples were 
vortexed then placed on a rotary wheel for 30 minutes at room temperature after which time 
they were centrifuged for 2 minutes at 10 000 rpm and placed on a MagRack (Life Sciences). 
After 5 minutes a visible dark brown pellet had formed on the side of the vial adjacent to the 
magnet. The solution was carefully pipetted out and the beads resuspended in 200 µL of fresh 
PBST. This wash stage was carried out twice to remove any excess DNA. The samples were 
then analysed using the Izon qNano. 
To each 200 µL sample 10 µL of the complementary DNA target was added at a 
concentration of 10 µM to provide a total concentration of 500 nM. The samples were 
vortexed and placed on a rotary wheel for 30 minutes. The samples were washed twice as 
described above and then analysed with the Izon qNano.  
3.3.2.3. Attachment of DNA to carboxylated beads 
45 µL of the bead stocks were diluted in MES hydrate buffer adjusted to pH 6 to a total 
volume of 450 µL. EDC was made up to 10 mg/mL concentration in MES hydrate buffer. 50 
µL of 10 mg/mL EDC was then added to the 450 µL of beads. 4.5 nmol of the Amine-
terminated DNA sequence was then added and the beads were left on a rotary wheel at room 
temperature for 2 hours. Following the incubation, the bead solution was removed from the 
rotary wheel and centrifuged for 5 minutes at 13 400 rpm at which point a white pellet had 
formed at the bottom of the vial. Any liquid was carefully pipetted out and the beads were 
resuspended in 450 µL of PBST, vortexed for 1 minute and sonicated for 1 minute. This 
procedure was repeated 3 times. 
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3.3.3. Tunable Resistive Pulse Sensing (TRPS) measurement 
All measurements were performed with the Izon qNano system, purchased from Izon 
Sciences, UK, which incorporates the fluid cell, stretching apparatus, data recording and 
analysis software (Izon Control Suite). Pores are supplied by the manufacturer each with an 
optimal size range for analysis. For the measurement of CPC100 beads an np100 (size range 
70 – 200 nm) was selected at 47 mm stretch; for 120 nm SPM beads an np200 (size range 
100 – 400 nm)  was used at a stretch of 44.50 mm and fixed applied voltage of 0.4 V, 
SKP400 beads were measured with an np400 (size range 200 – 400 nm) pore with 47 mm 
applied stretch and both CPC800s and Dynabeads MyOne were analysed with an np1000 
(size range 500 – 2000 nm) pore and 45.25 and 47 mm applied stretch, respectively. 80 µL of 
PBS was pipetted into the lower fluid cell ensuring that no bubbles were present and 40 µL of 
PBST into the upper fluid cell. Initially a stretch of 47 mm was applied across the pore and a 
voltage applied which gave a baseline current of between 80 and 120 nA. Once a stable 
baseline was established the sample could be introduced and the applied stretch and voltage 
adjusted so that peaks were visible above the level of baseline noise (≤ 10 pA), once the 
appropriate stretch and voltage were established these conditions were maintained across all 
measurements. Typically, a bandwidth filter of 1 kHz was applied during measurements.  
To analyse carboxylated beads they were first calibrated under a pressure of 2 cmH20 to 
attain the sample concentration following EDC conjugation chemistry. A sample of carboxyl 
beads which had not undergone EDC chemistry was then diluted to the same concentration. 
Sample concentrations were then matched in line with the manufacturer’s specifications for 
each pore used and both samples were then analysed under several voltages to give a baseline 
range of 30 to 130 nA for the pore being used. This range represents the working range of the 
instrument.  
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3.4. Results and Discussion: 
3.4.1. Detection of DNA on particles: monitoring rate against DNA concentration 
The first experiment modified the streptavidin coated beads with the biotinylated DNA of 
different lengths. Initially a 10-fold excess of biotinylated Thrombin-15 above the reported 
binding capacity of the beads was added to ensure that all the free binding sites were 
occupied. The beads were incubated at room temperature for 30 minutes before placing the 
sample in the TRPS instrument for measurement. During each experiment the pore stretch, 
ionic strength of the buffer, and applied voltage was constant. The applied voltage always had 
a positive bias applied to the electrode in the lower fluid cell underneath the pore, this 
orientation makes it easier to observe negatively charged beads
6
. Two distinct changes in 
signal were apparent upon the binding of the thrombin-15 aptamer to the beads. The first was 
an increase in rate from around 50 to 400 beads per minute, and the second was a decrease in 
FWHM values from 1.2 ms to 0.3 ms. These changes were expected from equation 2.7 which 
states that the surface charge and electrophoretic mobility contributes to the rate at which 
beads move through the pore. To demonstrate that these effects were dependent on the 
quantity of DNA immobilised on the bead surface, a series of experiments was performed 
where the concentration of DNA added was increased, the results for which are displayed in 
Figure 3.  1: Scatter plot displaying average rate against increasing concentrations of Thrombin-15 (black 
crosses), Thrombin-MArray (blue diamonds), or a random decamer (red circles), for each data set n = 3. 
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Figure 3.  1 and Figure 3.  2.  
As the concentration of DNA increases, and thus the coverage on the bead surfaces, the 
FWHM and rate decrease and increase respectively until a steady value is obtained. This 
experiment was then repeated with a longer thrombin aptamer, termed Thrombin-MArray, 
and a short 10-nucleotide long random sequence.  
 
Whilst similar trends were observed for all sequences and the FWHM data displays little 
difference, the magnitude of the change in rate is greatly reduced for the random decamer, 
increasing to only 180 beads per minute. It is not unexpected that a shorter sequence would 
produce a reduced response as the shorter sequence would yield a smaller charge density on 
the beads surface, therefore having a reduced effect on the translocation events. The increase 
in rate is less distinct from the Thrombin-15 for Thrombin-MArray aptamer, despite being 11 
nucleotides longer. It is possible that a difference in rate or FWHM was not apparent because 
the beads are already maximally loaded and that the resolution of the current set up is not 
sufficient to discriminate small differences once the oligonucleotides have reached a certain 
length.  
Figure 3.  2: Scatter plot displaying mode FWHM against increasing concentrations of Thrombin-15 (black 
crosses), Thrombin-MArray (blue diamonds), or a random decamer (red circles), for each data set n = 3. 
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Figure 3.  3: Scatter plot displaying FWHM (ms) vs blockade magnitude (nA) for a sample incubated with 
either 0.1 nM (black crosses) or 50 nM (red circles) of Thrombin-15. 
In addition to looking at averaged data, using TRPS it is possible to examine the data for 
individual particles. With this it is possible to observe that with increasing DNA 
concentration not only does FWHM decrease, but the distribution of FWHMs also narrows 
when the DNA concentration is increased as illustrated in Figure 3.  3. As can be observed 
when DNA concentration is low (0.1 nM) there is a vast range from 0.14 to 46.93 ms, 
whereas after incubation in 50 nM Thrombin-15 the range is from 0.18 to 1.2 ms. The range 
in FWHM at lower concentrations is likely due to non-uniform coating with DNA, whereas at 
high concentrations all available binding sites are likely occupied leading to greater 
uniformity with FWHM decreasing as more strands of DNA coat the beads.  
In these experiments we failed to observe any increase in blockade magnitude (Δip) upon the 
binding of DNA meaning that a change in bead size was not detected as displayed in Figure 
3.  4. A change in size was likely not detectable due to a lack of resolution for the current 
pore and set up used to resolve such small changes to overall bead diameter.  
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Figure 3.  4: A = Scatter plots displaying mean blockade magnitude (Δip) against DNA concentration. B = 
expanded view of A, error bars represent 1 standard deviation. 
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3.4.2. Detection of DNA on particles: rate against applied voltage 
From the previous experiments detailing the effect of added aptamer on particle rate it is clear 
that biotinylated aptamers are able to bind streptavidin coated beads and provide a 
measurable signal of an increase in rate and decrease in FWHM. As such, the next 
experiment was to validate a different method for detecting DNA on the surface of beads. To 
negate the need to create a concentration curve to confirm DNA binding each time, a second 
experiment for confirming the presence of DNA on beads was conducted. As discussed 
previously adding DNA to the surface of beads increases the negative surface charge density 
and increases the electrophoretic mobility; making the bead more susceptible to changes in 
voltage therefore measuring the rate of beads under different applied voltages should provide 
confirmation that beads are coated with DNA. To provide an expected trend the response of 
streptavidin coated beads under several applied voltages was measured to provide a 
reference. The results of this experiment are displayed in Figure 3.  5. 
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Concentration of the particles is also a factor in determining blockade rate so the particle 
concentrations of both samples were first matched to remove this variable. Two key 
differences are apparent between the blank beads and those functionalised with the aptamer. 
Firstly, the rate, as expected, is higher for beads with DNA across the full range of voltages. 
Secondly, the gradient is steeper for beads with DNA than those without suggesting that they 
are under greater influence of the applied voltage. The difference in rate between beads with 
or without DNA increases with increasing voltage, suggesting that in order to see a clear 
difference between beads with or without DNA, a high voltage should be chosen. 
Figure 3.  5: Scatter plot displaying the relationship between average rate and voltage for blank 300 nm 
streptavidin beads (crosses) or those functionalised with biotinylated aptamer (diamonds); n = 3 and error bars 
represent the range of recorded rates. 
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Following on from this carboxylated beads of different diameter were investigated. Figure 3.  
6 displays the results of altering voltage upon the rate of beads which underwent EDC 
conjugation chemistry. The translocation of beads through the pore orifice is dictated by a 
number of factors including surface charge, pressure, pore size, and the applied electric field, 
as discussed in chapter two. At low voltages the dominant force is likely to be from the 
inherent pressure head of gravity resulting in a small observable difference between the 
beads. As the voltage is increased, the surface charge of the bead becomes more dominant 
which makes it more susceptible to the applied field and results in an increased number of 
translocations.  
As displayed in Figure 3.  6 for all of the bead types investigated there is an increase in both 
rate and gradient with increasing voltage for beads which had undergone conjugation 
chemistry. It is worth noting that for carboxyl DynaBeads MyOne (Figure 3.  6D) the 
difference between those which had undergone conjugation to DNA and those which had not 
is far smaller than the carboxyl beads. This is possibly due to the additional mass of the 
superparamagnetic core, which then lessens the impact of electrophoretic mobility as the 
effect of gravity increases.  
Figure 3.  6: Scatterplots displaying the relationship between rate and voltage for 100 nm carboxyl beads 
(A), 350 nm carboxyl beads (B), 750 nm carboxyl beads (C) and 1 µm Dynabeads MyOne (D) with (circles) 
or without (crosses) DNA.  
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3.4.3. Detection of DNA hybridisation on the surface of beads 
After the detection of single-stranded DNA of different lengths an experiment was conducted 
to establish whether or not hybridisation of DNA strands would be able to be detected with 
TRPS. This is potentially of use in the detection of specific DNA fragments by the detection 
of double-stranded DNA formation.  
To do this a 15 nucleotide complementary sequence to Thrombin-15, with no further 
modification, was purchased for use as the target sequence. Firstly, a concentration curve for 
thrombin 15 against blockade rate was created with 8 concentrations of Thrombin-15. 
Samples were thoroughly washed so that any excess unbound DNA in solution is removed 
which would cause off-target binding and reduce sensitivity. After the measurement of these 
8 samples they were each then incubated with 500 nM of target DNA for 30 minutes then 
again washed and resuspended to the same volume. It was found that when target DNA was 
added the rate increased significantly as displayed in Figure 3.  7. The target DNA does not 
have any impact upon rate unless the complementary Thrombin-15 is present in sufficient 
concentration, suggesting that DNA does not non-specifically attach to the bead surface or 
streptavidin coating.  
Figure 3.  7: Scatter plot displaying average rate against increasing concentrations of Thrombin-15 with (black 
crosses) or without (black circles) incubation with 500 nM of a complementary sequence. N = 3; error bars 
represent 1 standard deviation. 
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3.5. Conclusions 
In the experiments conducted in the chapter TRPS has been successfully utilised to monitor 
the changes in surface functionality on beads. Changes in rate and FWHM are sensitive 
enough to monitor the immobilisation of DNA aptamers on the bead surface which is affected 
by DNA concentration, DNA length and whether it is single or double stranded. In addition, 
by measuring the rate of beads under different applied voltages it is possible to gain 
qualitative information to confirm whether or not carboxylated beads are successfully 
functionalised with lengths of DNA following one-pot conjugation chemistry. This study also 
highlighted the need for optimisation of a chosen voltage as the difference in rate between 
blank and DNA coated beads is greater at higher voltages and at low voltages there is not a 
significant difference between the bead rates.  
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Chapter Four 
Monitoring of aptamer-ligand interactions on the 
surface of beads 
 60 
 
4.1. Abstract: 
Having confirmed the aptamer conjugation onto the surface of beads in Chapter 3, a proof of 
concept protein assay was designed to detect aptamer-ligand interaction on the surface of 
beads. Here, a tunable resistive pulse sensing (TRPS) technology is used to monitor the 
interaction between several DNA aptamers and their target – thrombin. Aptamers were 
immobilised onto the surface of superparamagnetic beads, prior to their incubation with the 
thrombin protein. The protein binding to the aptamer caused a conformational change 
resulting in the shielding of the polyanion backbone; this was monitored by a change in the 
translocation time and pulse frequency of the particles traversing the pore. This signal was 
sensitive enough to allow the detection of thrombin down to nanomolar levels without the 
need for optical labelling. The power of TRPS was further demonstrated by performing real 
time detection as thrombin associates with its aptamer in the fluid cell. Real Time Detaction 
allowed characterisation of the aptamer-target interaction and measuring the association rates 
of the thrombin protein to the aptamer sequences.  
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4.2. Introduction: 
TRPS technology has herein been used to observe the interaction between aptamer modified 
superparamagnetic particles with their target protein, thrombin. Thrombin is a protein 
involved in feedback mechanisms for haemostasis and in the clotting cascade where it 
catalyses the formation of fibrin
1
. The concentration of thrombin must therefore be tightly 
regulated by biological systems and monitored as any deviations from normal physiological 
concentrations could pose a risk of blood clot formation leading to heart attack or stroke
2–4
. 
Aptamers to thrombin have also been widely used to validate emerging aptasensors
5
. It’s well 
characterised binding mechanism and high affinity makes thrombin an ideal protein target
6,7
. 
Attaching  aptamers to nanoparticles combines the selectivity of the aptamer capture probe 
with established detection methods of nanoparticles
8
. Assay formats include colorimetry
9
, 
lateral flow assays
10
, fluorescence
11
, light-scattering
12
 and electrochemistry
13
.   
In the presence of thrombin, aptamer sequences containing a “GGNNGGNGNGGNNGG” 
(where N represents T or A) motif undergo a conformational change to form a G-quadruplex 
structure
14
, see figure 2.1. As it possesses such a well-studied structure, it also allows the use 
of modified thrombin aptamer sequences. Here, the structure is deliberately controlled to 
study the effects upon the signal in the TRPS
7,15
 using three previously generated aptamers 
specific to thrombin, represented in figure 4.1 below.  
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Figure 4. 1: Schematic of the thrombin protein binding to three different aptamer sequences. 
As shown in Chapter 3, the immobilisation of DNA onto the particle surface can be 
confirmed by changes in the particle rate as well as a decrease in translocation times. In the 
case of streptavidin, these results confirmed the change in surface charge from a relatively 
neutral to negatively charged surface. In this chapter, we then go on to show that the 
incubation of the thrombin target with the aptamer modified beads then causes a shielding 
effect, where the thrombin protein masks the negative charge of the DNA aptamer causing 
the particle count rate and translocation times to change.  This interaction was measured 
following incubation of the beads with the protein for 30 minutes and then also monitored in 
real time with detection of nanomolar quantities of thrombin. The ability of TRPS to measure 
each individual object passing through the pore in real time allowed the monitoring and 
comparison of binding kinetics for three different aptamers to thrombin each with a change in 
binding mechanism. 
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4.3. Method: 
4.3.1. Chemicals and reagents 
The following chemicals were sourced from Sigma Aldrich, United Kingdom, without any 
further purification unless otherwise stated: PBS (P4417), Tween 20 (P1379), BSA (A2153), 
and thrombin (T7513).  
DNA sequences were purchased as lyophilised powders with HPLC purification from 
Entelchon (Germany) : 5’GGT TGG TGT GGT TGG TTT TTT TTT T-Biotin-3’ (Thrombin-
15)
16
 and 5’TGG GAG TAG GTT GGT GTG GTT GGG GCT CCC CTT TTT-Biotin-3’ 
(Thrombin-MArray)
15. The sequences 5’GGT TGG TTT ATT TTA CTA GTG GCC AGG-
Biotin-3’ (ThrombinEvol)7 and a random biotin-tagged 10mer were purchased as lyophilised 
powders with HPLC purification from Sigma-Aldrich (UK).  These were made up to a stock 
concentration of 100pmol/μL with deionised water purified to a resistivity of 18.2 MΩ. 
Streptavidin modified superparamagnetic beads of 120 nm (Bioadembeads streptavidin plus, 
03211) were purchased from Ademtech (France). Carboxyl beads of known diameter and 
concentration were purchased from Izon Sciences, UK: SKP200B (mode diameter 203 nm, 1 
× 10
11
 beads/mL). All beads were diluted in 1 × PBST (0.05% tween 20) electrolyte buffer. 
4.3.2. Thrombin binding assay 
4.3.2.1. Attachment of aptamer onto the beads 
The supplied beads were first vortexed and sonicated to ensure monodispersity. 120 nm 
streptavidin coated beads were diluted to a concentration of approximately 3 × 10
9
 beads/mL 
for use as a stock. A ten-fold excess (according to the binding capacity stated on the 
manufacturer specifications) of biotinylated thrombin binding aptamer was then added to the 
bead (to 100 µL of beads 17.1 pmol DNA is added). Each sample was then vortexed for 1 
minute and then placed on a rotary wheel for 30 minutes at room temperature prior to 
analysis with TRPS. 
4.3.2.2. Removal of excess DNA 
The sample was centrifuged for 2 minutes at 10 000 rpm and immediately placed in a 
MagRack (Life Sciences). After 5 minutes the beads had formed a visible cluster in the 
sample vial adjacent to the magnet and the solution was carefully removed and replaced with 
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an equal volume of PBST. This wash stage was performed twice and the particles 
resuspended in their original volume before being vortexed for 1 minute and sonicated for 30 
seconds.   
4.3.2.3. Thrombin concentration curve 
100 µL samples of aptamer-functionalised beads were pipetted into sample vials. Different 
concentrations of thrombin were added to provide a concentration range of 0.1 – 10 000 nM 
with the volume added constant across the range to ensure that any results were not due to 
dilution of the beads. The samples were incubated on a rotary wheel at room temperature for 
30 minutes before analysis.  
4.3.2.4. Real time thrombin binding assay 
36μL of washed bead-aptamer sample, prepared as described in section 4.3.2.1., was pipetted 
into the upper fluid cell of the TRPS instrument, this dispersion was recorded for 60 s at 
which time the software was paused and 4μL of the required test solution was added into the 
solution. Recording was immediately resumed. Data was then captured for 60 seconds to 
achieve a baseline value. The recording was then paused and 4 µL of thrombin added into the 
fluid cell and the recording resumed. The addition of the 4 l of solution required the pipette 
tip to be placed into the liquid, the 4 l was then added and the tip removed. Other than the 
convection caused by the removal of the tip no additional stirring was induced.  
4.3.3. Tunable Resistive Pulse Sensing (TRPS) measurement 
Measurements were made using the qNano system obtained from Izon Science 
(Christchurch) with control suite analysis software (v2.2.) as described in chapter 3, section 
3.3.3.  For these experiments the pores used were designated ‘NP200’ by the manufacturer, 
and are described as most suitable for detecting particles in the range 100 – 300 nm. 80 µL of 
PBS was pipetted into the lower fluid cell ensuring that no bubbles were present and 40 µL of 
PBST into the upper fluid cell. A macroscopic stretch of 44.50 mm was chosen with an 
applied voltage of 0.36 V. These conditions were chosen so that peaks were visible above the 
baseline noise (10 pA) with an applied bandwidth filter of 1 kHz during all measurements. 
After recording, this solution was withdrawn and the fluid cell and pore washed by repeatedly 
replacing PBST in the upper fluid cell until no particles were apparent on the signal trace. To 
generate error bars in all figures the mean and standard deviation of repeat experiments was 
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used. Data was examined in the Izon Control Suite (v2.2.) and for detailed examination of 
real time measurements exported to Microsoft Office Excel 2010 as a .csv file. 
4.4. Results and Discussion: 
4.4.1. Thrombin binding assay 
Having modified the beads with Thrombin-15 aptamer and washed out any excess DNA as 
described in the method section, the functionalised beads were then incubated with increasing 
concentrations of thrombin. Figure 4. 2A and B display the resultant plots of particle rate and 
mode FWHM against thrombin concentration respectively for thrombin-15 (line a - solid red 
line). As the concentration of thrombin increases, the particle rate and FWHM values 
decrease and increase respectively. This is attributed to the binding of thrombin with the 
thrombin-15 aptamer whereby the thrombin proteins sit atop the DNA sequence and shields 
the negative phosphate backbone of the aptamer, as displayed schematically in Figure 4. 2C. 
At higher concentrations of thrombin (greater than 10 nM) the gradient at which the rate 
decreases becomes shallower meaning that further binding of the thrombin protein is not 
observed. However, the FWHM for beads functionalised with thrombin-15 continues to 
increase beyond this point which might suggest an increased range of measurement when 
using FWHM values. It is worth noting that due to the low particle count rate at high 
concentrations of thrombin the mode FWHM values are more variable than the particle rate 
and therefore might be more easily skewed by a small population of outliers in the sample. 
A second sequence, thrombin-MArray was also investigated in this series of experiments, 
results for the thrombin-MArray aptamer are displayed in line b (black, solid) of Figure 4. 2A 
and B. Thrombin-MArray was optimised from one of the original thrombin aptamers by 
DNA microarray using a genetic algorithm
15
; this sequence contains the G-quadruplex motif 
common to thrombin binding aptamers which is flanked by complementary strands that form 
a stabilising region of double stranded DNA when the aptamer folds. This aptamer has been 
previously characterised by surface plasmon resonance (SPR) where it was found to have 
comparable affinity to the original thrombin-15
15
. It has been demonstrated that modifications 
of the original thrombin-15 aptamer can enhance the binding ability on surfaces
15,17
, with the 
potential to lead to greater sensitivity.  
When comparing the change in rate for thrombin-MArray and thrombin-15 similar trends 
were observed i.e. the particle rate decreases with increasing thrombin concentration, 
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however, the total change in FWHM across the range of concentrations was much smaller 
and did not display a clear increase. Again, as stated above, this may be attributed to the 
lower number of particles recorded due to the diminution of particle rate, as such, only 
particle rate shall be discussed in detail from this point on. It was noted that for thrombin-
MArray there was very little deviation in the particle rate at low concentrations of thrombin 
and a sudden sharp near-abolition of particle translocations above 10 nM of thrombin.  
Figure 4. 2: A Scatter plots displaying the effect of increasing concentrations of thrombin or BSA on rate for 
Thrombin-15 incubated with thrombin (a) P = 0.03, Thrombin-MArray incubated with thrombin (b) P = 0.04, 
and Thrombin-15 incubated with BSA (c) P = 0.55. B FWHM plots for a  = Thrombin-15 (P = 0.004), b  = 
ThrombinMArray (P = 0.90), and c  = BSA control (P = 0.34). A “NP200” pore with a membrane stretch of 
44.50mm, voltage of 0.36V, and 40µl of sample in the upper fluid cell was used.  Each data point represents the 
average value from four experiments and error bars represent 1 standard deviation from the mean. P values 
calculated by one way ANOVA. 
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The differences between the changes in rate between thrombin-15 and thrombin-MArray may 
be attributed to differences in the binding mechanism. As previously stated, thrombin-
MArray folds in half to form complementary base pairs near the bead surface, holding the 
thrombin protein close to the surface of the beads the unbound thrombin-MArray sequence is 
significantly longer than the original thrombin-15, meaning that neighbouring unbound 
strands extend out past the bound thrombin into solution. When protein concentration, and 
therefore bead coverage, is low, the dominant effect of the particle rate and FWHM is the 
protruding anionic phosphate backbone from the aptamer past the protein. As the protein 
coverage increases and more of these aptamer strands change conformation and are shielded, 
the particle rate diminishes. 
Across these experiments no change in the size of the beads was observed, although one 
would assume a small increase in size due to the added DNA and protein would occur. The 
size of the object passing through the pore is inferred by the blockade magnitude (Δip) which 
is proportional to particle volume. As displayed in Figure 4. 3, the recorded Δip does not 
show any significant change with thrombin concentration. This is most likely due to a lack of 
resolution of the current set up to discriminate such small changes in size.  
Figure 4. 3: Concentration curve displaying the effect of increasing concentrations of thrombin on the Δip of 
beads functionalised with Thrombin-15. The data used to collate this graph were obtained using a manufacturer 
classified “NP200” pore with a membrane stretch of 44.50mm, an applied voltage of 0.36V, and 40µl of sample 
in the upper fluid cell. Each data point represents the average value from four experiments and error bars 
represent 1 standard deviation from the mean. 
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As a control, the same experiment was conducted using increasing concentrations of BSA 
protein, the results for which are also displayed in Figure 4. 2A and B (line c – red, dashed) 
for thrombin-15 and Figure 4. 4 for the thrombin-MArray aptamer. The particle rate and 
FWHM remain constant across the concentration range of BSA, illustrating that the aptamer 
is specific to the thrombin target and that any change in signal is not the result of a 
nonspecific interaction between the protein and DNA or surface of the beads. 
  
Figure 4. 4: Concentration curve displaying the effect of increasing concentrations of BSA on the rate (solid 
line) and mode FWHM (dashed line) of Thrombin-MArray functionalised beads. The data used to collate this 
graph were obtained using a manufacturer classified “NP200” pore with a membrane stretch of 44.50mm, an 
applied voltage of 0.36V, and 40µl of sample in the upper fluid cell. Each data point represents the average 
value from four experiments and error bars represent 1 standard deviation from the mean. 
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4.4.2. Real time thrombin binding measurement 
The experiments in section 4.4.1. were recorded after a 30 minute incubation between the 
beads and target protein, this should have been sufficient time for the binding between the 
protein and aptamer to have occurred. Calculations based upon Smoluchowski theory
18,19
 
suggest that the reaction should proceed quickly under the conditions and concentrations used 
here and binding between the protein and aptamer should occur within seconds. To explore if 
binding could be observed in real time 36 µL of Thombin-15 modifed beads were placed into 
the upper fluid cell of the TRPS instrument, data was collected for 60 seconds to obtain a 
baseline particle rate, after this 60 second period data capture was paused whilst the thrombin 
protein was added to the upper fluid cell before continuing data collection. The change in 
particle rate as a function of time for four experiments repeated for a thrombin concentration 
of 15 nM are displayed in figure 4.5A. 
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Figure 4. 5: A, Replica experiments of real time particle rate measurements for Thrombin-15 modified beads. 
At t = 0 36µl of sample was present in the upper fluid cell, at t = 60s 4µL of Thrombin solution was added 
giving a final concentration of 15 nM. B, One set of experiment demonstrating the change in rate with respect to 
the concentration of thrombin. At t = 60s 4µL of Thrombin solution was added giving a final concentration of 
thrombin (navy blue) = 1.5 nM, b (red) = 3 nM, c (green) = 15 nM, d (blue) = 77 nM, e (purple) = 154 nM. C, 
Plot of rate of change in particle count, ln(R/R0), versus time, for the experiment shown in part B. t = 0 indicates 
the point at which thrombin was added to the particle solution. D, Plot of Kobs versus concentration of thrombin. 
The values represent the mean from four experiments. The data was obtained using a “NP200” pore with a 
membrane stretch of 44.50mm, an applied voltage of 0.4V. 
After the addition of thrombin into the upper fluid cell at 60 seconds the observed particle 
rate decreased until a continuous particle rate was reached after approximately 120 seconds. 
The observed change in rate is attributed to the same effects as described above for a set 
incubation period: the binding of the protein to the aptamer masks the negative DNA 
backbone resulting in decreased mobility. Figure 4.5B illustrates the change in particle rate as 
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a function of thrombin concentration ranging from 1.5 to 154 nM. As the thrombin 
concentration increases both the magnitude of the change in rate, and also the speed of that 
change, also increase. Figure 4.5B shows example measurements which were performed in 
triplicate, in reaction rate calculations the average value of triplicate measurements for each 
thrombin concentration were used.  
The concentration of thrombin is in excess of the number of beads by several orders of 
reaction, hence, a first order reaction was assumed where a plot of the rate of change, 
ln(R/R0), against time would yield a straight line with gradient of kobs. R was calculated by 
the following equation: 
 𝑅 =  (
60
𝑡𝑝
) × 𝐶𝑜𝑢𝑛𝑡𝑡𝑝  4.1 
 
Where tp is the recorded time of particle translocation and Counttp is the total number of 
particles at tp. R0 is the average rate of particles per second recorded in the 60 seconds 
previous to thrombin addition. Kobs = ka[Thrombin]+kd. Thus a plot of Kobs versus 
concentration of thrombin should yield a straight line with the gradient of ka and an intercept 
of kd. Figure 4.5C displays the change in rate for the 5 thrombin concentrations shown in 
figure 4.5B. In the calculations a minimum of 60 seconds was collected after the injection of 
the protein to calculate the reaction rates.   
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Figure 4. 6: Real time particle rate measurements taken for three aptamers, curves are labelled a, b and c, 
representing data from Thrombin-MArray, ThromEvol and Thrombin-15 respectively. At t = 0 36µl of sample 
was present in the upper fluid cell.  A, 4µl of thrombin solution added at t = 60 s giving a concentration of 3 nM. 
B, 4µl of thrombin solution added at t = 60 s giving a concentration of 15 nM. C, 4µl of thrombin solution 
added at t = 60 s giving a concentration of 45nM. D, 4µl of thrombin solution added at t = 60 s giving a 
concentration of 154 nM. The data was obtained using a “NP200” pore with a membrane stretch of 44.50 mm, 
an applied voltage of 0.4V.  
The gradients from each experiment are plotted as a function of concentration in figure 4.5D 
and from the regression line ka was calculated to be 7.42 × 10
4
 M
-1
s
-1
, kd 2.9 × 10
-3
 s
-1
 and 
gave a KD 39.1 nM, which is comparable to measurements reported in the literature of 6 
nM
65
, 20 nM
61
, 200 nM
66
, 102.6 nM
67
, and 75-100 nM
68
.  
The same set of experiments was performed for the Thrombin-MArray aptamer the results 
from which are displayed in figure 4.6. It was noted that when a low (<10 nM) concentration 
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of thrombin was used there was no observed change in signal after the injection of thrombin 
protein at 60 seconds for the Thrombin-MArray aptamer as displayed in figure 4.6A in 
agreement with data attained after a set incubation period in figure 4.2A. 
Plotting kobs against thrombin concentration for the thrombin-MArray aptamers as displayed 
in Figure 4.7A obtained a ka of 4.03 × 10
4
 M
-1
s
-1
, kd 3.40 × 10
-3
 s
-1
 and KD 84.3 nM. This 
compares favourably to the value obtained previously using surface plasmon resonance 
techniques, SPR,  of 28 nM55.  
It was hypothesised that differences in thombin-15 and thrombin-MArray, which have similar 
ka and kd values to traditional SPR methods, is due to mechanistic effects, i.e. the protein is 
buried within a negative DNA layer with unbound thrombin-MArray protruding past the 
bound thrombin proteins, or the hindrance of the protein binding to the thrombin-MArray 
aptamer on a beads surface rotating at ~ 400 s
-1
. As the concentration of thrombin was 
increased from 15 to 154 nM in Figure 4.6B – D the rate of change for the thrombin-MArray 
began to increase and eventually matched that observed for the thrombin-15. 
A third aptamer, Thrombin-Evol, was also tested. This aptamer was raised via the CLADE 
technique and while it does not contain the typical G-quadruplex motif it still possesses a 
reported ka of 8.7 × 10
4
 M
-1
s
-1
, kd 2.04 × 10
-3
 s
-1
 and KD 23.45 nM
46
 when measured with 
SPR. Importantly, this aptamer binds to the protein via the base pairs at the end of two 
neighbouring sequences illustrated in figure 4.1iii. It was hoped that this binding mechanism 
Figure 4. 7: Plot of Kobs versus concentration of thrombin for A – Thrombin-Marray sequence and B – 
Thrombin-Evol. n = 3. 
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would lead to an improved sensitivity as unlike the Thrombin-MArray sequence the protein 
sits on the end of the aptamer strands. The real time particle rate measurements for the 
sequences are presented in figure 4.6A – D (curves b). The ThrombinEvol sequence has an 
improved response at the lower protein concentrations and consistently performs better than 
the Thrombin-MArray, as observed in figure 4.6. The measured reaction rates based upon 
triplicate measurements for the Evol aptamer were ka of 5.78 × 10
4
 M
-1
s
-1
, kd 4.80 × 10
-3
 s
-1
, 
and KD 83.1 nM as calculated with the plot of Kobs versus concentration displayed in figure 
4.7B. Whilst this suggests the shielding of the charge via the protein is key in observing a 
change in particle rate, the clearest response across the full range of the protein 
concentrations was the original Thrombin-15 aptamer. These results suggest that whilst 
shielding the charge on the DNA is an essential part of the signal, to obtain a strong change in 
particle rate a conformational change must also take place.  
To demonstrate that the results of these experiments could not be due to the addition of extra 
solution itself and that it did not cause a significant change in particle count rate, the same 
volume of PBST without Thrombin was added into the upper fluid cell, data from repeat 
experiments shown in figure 4.8 and is summarised in table 4.1. The addition of fluid into the 
upper fluid cell alters the height of the fluid level therefore increasing fluidic forces and 
causing a slight dilution effect. Typically the addition of the extra 4 l of solution to the 
upper fluid cell caused a small deviation in the gradients of the line, on average the gradient 
of the line changed by around -4% upon the addition of the solution indicating a decrease in 
particle count rate.  
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Table 4. 1: Gradients of regression lines for data displayed in Figure 4. 8 
Three control experiments were also conducted to be sure that any observed effects were 
specific to the thrombin-aptamer interaction on the surface of the beads, the results for these 
are displayed in figure 4.9. In curve 1 the upper fluid cell was loaded with 36 µL of 
thrombin-15 modified beads and data was collected for 60 seconds, following this period of 
time recording was paused and 4 µL of BSA protein was added to the upper fluid cell. In 
curve 2 thrombin was added to carboxyl coated polystyrene beads, and curve 3, thrombin is 
added to a superparamagnetic bead modified with a random 10mer. In each experiment the 
protein concentration was 15 nM and no deviation or change in particle rate after the 
additional of the protein was observed.  
 
 
  
Experiment Gradient <60 sec Gradient >60 sec Change in gradient %
1 4.97 4.68 -6.2
2 5.70 5.40 -5.5
3 4.70 4.32 -8.7
4 4.02 4.05 1
5 4.20 4.10 -2.4
Figure 4. 8: A - Experiments of real time particle rate measurements for Thrombin-15 modified beads. At 
t = 0, 36 µL of sample was present in the upper fluid cell, at t = 60 sec 4 µL of PBST was spiked into the 
fluid cell. B – Data from A plotted as particle rate per minute.  
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Figure 4. 9: Real time particle rate measurements. At t = 0, 36 µL of sample was present in the upper fluid cell , 
4 µL of the Protein solution was added to the upper fluid cell at t = 60 Line 1 – Thrombin-15 aptamer beads 
with 4 µL of BSA solution added at t = 60 seconds giving a concentration of 15 nM, Line 2 – Carboxyl coated 
beads with 4 µL of thrombin solution added at t = 60 seconds giving a concentration of 15nM, Line 3 – Random 
10mer with 4 µL of thrombin solution added at t = 60 seconds giving a concentration of 15nM. A manufacturer 
classified “NP200” pore with a membrane stretch of 44.50mm, applied voltage of 0.36V was used for the 
experiment. 
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4.5. Conclusion 
TRPS was successfully used to monitor changes to surface functionality of 
superparamagnetic beads. This signal was utilised to study the interaction of aptamers with 
their target protein, thrombin. The changes in particle rate were sensitive enough to monitor 
the binding of protein to three different aptamer sequences on the surface of beads. FWHM 
also appeared to increase with increasing thrombin concentration for the Thrombin-15 
aptamer, however, due to the small sample size recorded in high thrombin concentrations 
when the rate is low this is perhaps less reliable. These results demonstrate that TRPS is now 
one of many technologies capable of monitoring the interaction between aptamers and their 
target protein. Further, it was demonstrated that TRPS allows for real time monitoring of the 
protein-aptamer interaction allowing the reaction rates to be calculated. This offers a new 
technique for monitoring the association rates of analytes directly on the beads surface 
without the need for identification labels such as fluorescence or utilising standard SPR 
technologies. The current method does have a limited working range, as at higher 
concentrations of target a reduced particle count rate makes obtaining a sufficient particle 
count difficult within the constraints of the Izon Control Suite software hence future work 
endeavours to generate a signal which increases rather than diminishes with increased target 
concentration.   
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Chapter Five 
TRPS as a tool to monitor analyte induced particle 
aggregation 
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5.1. Abstract: 
As highlighted in chapter one, SPBs can perform the capture, purification and signal 
transduction stages, producing a relatively simple, fast, and sensitive label-free format. 
Whilst prior chapters have focussed on changes in particle mobility to detect bound proteins, 
here the focus is on changes in Δip in the presence of the target; one possible way to do this is 
to induce aggregation. Particle aggregation in the presence of the analyte is a common 
example of such a detection strategy. Herein we demonstrate the key parameters which lead 
to aggregation. Tunable Resistive Pulse Sensing (TRPS) technology was utilised to follow 
the aggregation using three different methods of analysis. TPRS allows a comparison in the 
data treatment using average population values, particle concentration, and a more detailed 
analysis monitoring the change in aggregate size and frequency. To validate the approach, the 
well-known biotin-avidin binding assay is used to demonstrate the advantages and limitations 
of each type of analysis. Also presented are the key parameters that contribute to assay 
sensitivity such as bead concentration, size, binding capacities and data analyses. 
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5.2. Introduction: 
Previous chapters have focussed on the impact of aptamer functionalisation and target 
binding to beads on the mobility of these beads in the TRPS system. However, an alternative 
signal could be the selective change in size of beads, and therefore Δip, as they move through 
the pore. One way to do this is by inducing bead aggregation. 
Aggregation assays where the concentration of the analyte is related to changes in aggregate 
size and frequency
1
 are well documented. Many of the techniques rely on optical and light 
scattering techniques which provide an average value of the population and offer little insight 
into the formation of individual clusters with techniques such as microscopy severely limited 
by the relatively small sample size and amount of time taken to manually count each cluster. 
In addition, light scattering techniques such as dynamic light scattering rely on highly 
uniform particle dispersion as the average is easily skewed by the presence of outliers
2
. As 
such, for looking at a mixed dispersion TRPS offers many advantages. TRPS lends itself well 
to the identification of aggregates due to the ability to extract information for each object 
passing through the pore rather than a calculated average with assumed normal distribution.  
In this chapter a comparison of different strategies aimed at interpreting the aggregation 
signal using TRPS is presented and key parameters that control the aggregation of SPBs for 
the streptavidin-biotin assay are identified, i.e., bead concentration, size, binding capacity, 
reaction time, and application of magnetic force. The avidin-biotin interaction was used as a 
model as it is among the strongest known non-covalent specific molecular interactions, i.e., 
Kd ~ 10
-15
 M/s
-1
.  Under the optimal assay conditions the assay could be used to detect 
biotinylated proteins across five orders of magnitude in concentration with sensitivities in the 
sub picomolar range. The concentration of analyte and the most stable and reproducible sizes 
of aggregates were correlated for different bead compositions. This insight will help users 
optimize the TRPS setup for monitoring the aggregation signal, and offers an insight into the 
aggregation state of particles in the presence of the analyte.   
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5.3. Method: 
5.3.1. Chemicals and reagents 
The following chemicals were sourced from Sigma Aldrich, UK, without any further 
purification unless otherwise stated: Phosphate Buffered Saline (PBS – P4417), Tween 20 
(P1379), MES hydrate (M2933), sodium dodecyl sulphate (SDS – 71727), (Bovine Serum 
Albumin (BSA – A2153), and thrombin (T7513). 1 step ABTS solution, biotin-HRP, biotin 
BSA,  EDC (22981), Sulfo n-hydroxylsucciminide, N-hydroxysulfosuccinimide (sulfo-NHS) 
and avidin, were purchased from Thermo scientific. Water purified to a resistivity of 18.2 
MΩ cm (Maxima) was used to make all solutions unless otherwise specified. 
Carboxyl dynabeads of 1µm (catalogue number 650.12) and 3µm (catalogue number 
143.05D) were purchased from Invitrogen, UK. Bio-Adembeads, 300nm (3233) were 
purchased from Ademtech, France. These beads were separated and washed using a Magrack 
purchased from GE healthcare. The concentrations of these commercial beads are as follows: 
For the 3 µm beads 1mg = 5 x 10
7
 beads, for the 1 µm beads 1mg = 6 x 10
8
 beads, and For 
the 300nm beads 1mg = 1 x 10
10
 beads. Carboxyl beads of known concentration and diameter 
(SKP400; mode diameter 350 nm, CPC1000; mode diameter 955 nm) were sourced from 
Izon Sciences (Oxford, UK) to be used as a calibrant.  
5.3.2. Modification of beads with avidin 
Both the 1 and 3 µm diameter beads were modified with the avidin protein prior to the assay 
being performed. The beads (1 mg/mL) were washed three times with MES buffer. Following 
the third wash step the beads were resuspended in 1 mL MES buffer and EDC (1 mg) and 
NHS (1 mg) were added to the solution. The particles were sonicated gently for 30 seconds 
and left on a rotary wheel allowing end-over-end mixing for 30 mins. This resulted in NHS 
activated beads. After 30 mins the particles were washed with MES buffer twice before a 
1mL PBS solution containing the required amount of avidin protein was added to the 
particles. The particles were sonicated gently for 30 sec and left on a rotary wheel allowing 
end-over-end mixing for 3 hours. After which time the beads were washed with PBST three 
times before being resuspended in PBST containing 0.05% (wt/wt) BSA protein to block any 
nonspecific adsorption. 
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5.3.3. Quantifying bead binding capacity 
The binding capacity of all beads were measured using the standard biotin-HRP and ABTS 
quantification using a NanoDrop 2000 UV-Vis Spectrophotometer. Briefy, 50 µL of 
avidinated beads (at 1 mg/ml) where washed with PBST once and incubated with a fresh 
PBST (0.05% wt/wt BSA) solution for 30 mins to block the surface and eliminate any non-
specific adsorption. After 30 minutes the beads were washed twice with PBST and incubated 
with 0.05 µg of Biotin-HRP protein in PBST for 30 minutes. After 30 mins the beads were 
washed three times with PBST and resuspended in 100 µL of PBST. To this solution 200 µL 
of ABTS solution was added and the vial was placed onto a rotating wheel for 1 minute. 
After 1 minute 200 µL of 1% (wt/wt%) SDS “STOP” solution was added to the beads and the 
absorbance at 410nm was recorded. This final absorbance value was converted into a binding 
capacity using a calibration curve with standards of known biotin-HRP protein concentrations 
prepared by serial dilution, the results for which are displayed in figure 5.1 below. 
 
Figure 5. 1: Example calibration curve plotting biotinylated HRP concentration versus measured absorbance. 
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 5.3.4. Binding assay 
The avidin coated particles (1 mg/ml) were routinely stored in PBST buffer containing 0.05 
(wt/wt%) BSA to act as a blocking solution and reduce non-specific adsorption. When 
required the particles were diluted to the required concentration, and sonicated briefly (<10 
seconds). Typical assay volumes were ~500 – 1000 µL. The final dilution of the beads and its 
resultant concentration is reported in all graphs and calculations. Samples were prepared by 
diluting the target biotinylated-BSA into PBST and then adding to the particle dispersions. 
The solution was incubated at room temperature on a rotating wheel allowing end-over-end 
mixing. After the required hybridization time (30 minutes), the sample was either analysed 
immediately, or subject to magnetic assisted aggregation. Each experiment was run multiple 
times and the standard deviation of each point is shown in the errors bars on the graphs. 
For the magnet assisted aggregation (MAS) - the sample was placed next to a permanent 
magnet, with field strength of 1 milli-tesla present up to 60 mm from the neodymium magnet 
bar on its surface, until all the beads were judged to have come out of solution ~ 1 minute. 
The initial solution was removed leaving all the beads on the side of the container and 500 µL 
PBS was added to the beads. The solution was stirred and the magnet was replaced separating 
the beads for a second time. When required the magnet was replaced for a third and fourth 
time. During the last separation, the magnet was removed and the pellet allowed to settle to 
the bottom of the vial for 30 seconds before finally being vortexed for analysis. This process 
is aimed to increase particle-particle interactions and thus increase the number of particle 
aggregates.  
5.3.5. Overcoming the hook effect 
The hook effect is a phenomenon observed in aggregation assays whereby a high 
concentration of analyte can result in a reduction in the number of aggregates as the available 
binding sites are saturated leaving none available for aggregate formation. During the 
magnetic assisted aggregation process described above, after the first separation the analyte 
solution was removed and an additional 500 µL solution of avidinated beads in PBST was 
added to the sample vial. This additional aliquot of beads contained the same number of 
beads in the original solution, thus doubling the concentration of beads. The remaining 
process was the same as described above. 
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5.3.6. Tunable Resistive Pulse Sensing (TRPS) measurement 
Measurements were made with the Izon qNano system, purchased from Izon Sciences 
(Oxford, UK) which incorporates the fluid cell, stretching apparatus, data recording and 
analysis software (Control Suite). The pores used for measurement of the 3 µm beads were 
designated by ‘NP4000’ and most suitable, as determined by the manufacturer, for detecting 
particles in the range 2000 – 8000 nm, ‘NP1000’ pores were used to analyse 1 µm beads and 
most suitable for detecting particles in the range 500 – 2000 nm, finally ‘NP400’ pores were 
used to measure the 300 nm beads these are most suitable for detecting particles in the range 
200 – 800 nm. The macroscopic stretch applied to the membrane varied from 0 - 8 mm, 
additional to the separation of approximately 41.5 mm when the membrane is unstretched
3
. 
Once a baseline current of approximately 100 nA ± 10 was established for each membrane 
the potential and stretch was kept constant during the experiment. Typical setup for each 
membrane was: NP4000, Stretch 45.00 mm, Voltage 0.04V; NP1000, Stretch 46.50 mm, 
Voltage 0.04 V, NP400, Stretch 46.00 mm, Voltage 0.32 V. Izon’s calibration beads 
(obtained with the instrument) were used to calculate the initial concentration and size of all 
the particles, particles 955 nm in diameter, and 350 nm in diameter were used for this 
purpose. 
5.3.7. Data Analysis 
Data capture was performed using Izon Science’s Control Suite v2.2 software. The number of 
data points captured for each experiment exceeded 500.  
Upon processing the raw data with the software a “.txt“ file was created which contained 
information on each pulse recorded during the experiment. The peak height and time was 
extracted from the data and copied into a spreadsheet. Microsoft Excel 2010 was used to 
analyse the data further. The average peak height was calculated from all the data points 
captured and plotted against concentration to find the average size of the particles.  
To monitor changes in aggregate size, the data was first extracted as a .txt file as described 
above. A blank sample with no biotin was used to determine the location and size of the 
monomer and larger aggregate peaks. As the blank sample contained no analyte and therefore 
the signal represented the monomer, a bin size which accounted for these data points was 
determined. As the peak height is proportional to the volume displaced by the traversing 
particle
4,5
 a dimer would produce twice the signal, and a trimer three times the signal 
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intensity of the monomer, and so on for each larger aggregate. A histogram could then be 
constructed using multiples of the monomer peak to determine the number of larger 
aggregates. Once the number of data points for each bin had been determined from the raw 
data, the number was converted into a percentage by dividing it by the total number of data 
points for the experiment. The ratio was then plotted as a function of analyte concentration. 
In each experiment the fraction of aggregates up to and including the dodecamers was 
calculated, even if they are not plotted in the figures. All assay conditions and concentrations 
were repeated a minimum of three times and the average of each experiment is plotted on the 
graphs, the error bars and the standard deviation in the results. 
5.4. Results and Discussion: 
5.4.1. Aggregation of avidin modified SPM beads by biotinylated BSA addition 
Avidin functionalised SPM beads were added to a solution containing biotinylated-BSA. 
From the supplier information, each BSA protein contains an average of 9 biotin molecules, 
allowing multiple avidin molecules to interact with the biotinyated-BSA. The solution was 
incubated on a rotary wheel for 25 minutes and then placed in a MagRack to separate the 
beads from the solution and bring them into close proximity with each other. Following this a 
40 µL aliquot of the sample was placed into the upper fluid cell of the TRPS instrument. 
Figure 5.2A (blue curve) displays a plot of the mean Δip signal versus analyte concentration. 
As the concentration of the analyte was increased the average Δip remained constant until a 
sharp increase in Δip around a concentration of 1 x 10
-10
 mol/dm
-3
 biotinylated-BSA. The 
mean pulse height continues to increase up to a concentration of 1 x 10
-8
 mol/dm
-3
 before 
decreasing back to its original value. The increase in Δip was attributed to the particles 
forming larger aggregates in the presence of the analyte, at lower concentrations of analyte 
the number of aggregates was too low to be detected as the majority of the signal comes from 
individual monomers. The decrease in signal from aggregation at high concentrations of 
analytes has been well documented for agglutination assays. This decrease in aggregate size 
results from the saturation of the binding sites on the particle surface with the analyte and is 
known as the ‘hook’ effect6. As stated above there was no change observed when plotting the 
mean Δip as a function of concentration at biotinylated-HRP concentrations below 1 x 10
-10
 
mol/dm
-3 
suggesting that this method is insensitive to small changes below this concentration.  
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Figure 5. 2: Assay using 3 µm diameter beads, binding capacity of 14 µg/mg, assay time of 25 minutes, 5 x 10
8
 
beads/mL. A Change in average pulse height, Δip = Blue, and bead concentration = green, against concentration 
of biotinylated analyte. B Example of raw data from an individual experiment, red histogram displays the pulse 
height (Δip) for a blank sample, the black distribution shows the change in Δip for an analyte concentration of 1 
x 10
-9
 moldm
-3
. Overlaid is the example gate size for the monomer, dimer etc used to count the number of 
particles for plot C. C Plot of percentage of signal of monomer = red, dimer = green, trimer = blue and tetramer 
=purple. 
An alternative method explored was to follow the change in particle concentration with 
biotinylated-BSA concentration. As the particles aggregated the total number of beads in 
solution decreased, as monomers were consumed into growing particle clusters. The TRPS 
instrument was calibrated to measure the change in particle concentration. The same data 
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used for the above Δip measurements was re-analyzed, the results are plotted in figure 5.2A 
(green curve). Measuring the change in bead concentration appears to be more sensitive, and 
a decrease in bead count could be observed at concentrations as low as 1 x 10
-12
 mol/dm
-3
. In 
order to minimise variation it was important to consider factors affecting these results. If 
insufficient time was given for the beads to come out of solution in the presence of the 
magnet, some beads are washed out of the vial during the MAS stage the variation from run 
to run could be affected. If the technique is to be used across multiple labs the variation in the 
technician’s ability to wait for all the beads to be extracted from the solution could result in 
massive variations in the results, and given that it is hoped to develop these techniques for 
POC assay, user reproducibility must be high, therefore a robust method of data analysis is 
needed. 
In this study commercial Dynabeads and Ademtech beads were used; these have relatively 
uniform sizes with <2% and <10% CV respectively. Due to the high level of uniformity in 
diameter, it was possible to isolate the signal from the larger aggregates from that of the 
individual beads. Figure 5.2B displays the raw data from the Izon Software for a “blank” 
(red) bead set and a “sample” bead set incubated with 1 x 10-9 moldm-3 biotinylated-BSA 
(black). In the blank sample the beads produced an individual peak which was identified as 
“monomers”. The data was then gated for the monomer peak and 94% of all the data points 
were accounted for within this gate. The remaining 6% is most likely due to nonspecific 
aggregation, or off-axial translocation leading to a spread in the signal. This gate was titled 
“Monomer”; as the Δip is proportional to volume of the particle traversing the pore, a dimer 
should in theory produce a Δip twice the magnitude of a monomer. Therefore by doubling the 
gate size the number of dimers could be counted. A similar process was performed to account 
for aggregate sizes up to decamers.  
Figure 5.2C summarises the quantitative analysis of the percentage of monomers, dimers, 
trimers and tetramers formed in the assay using the 3 µm beads, as a function of analyte 
concentration. It was observed that the formation of aggregates was closely correlated with 
the decrease in monomers, i.e., the minimum number of monomers appeared at an analyte 
concentration at which the maximum number of dimers, trimers, and tetramers were 
observed.  At concentrations between 10-12 and 10-9 M there was a direct correlation between 
the number of dimer aggregates and the biotinylated-BSA concentration.   
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Again as inferred from figure 5.2A at concentrations greater than 1 nM there was a decrease 
in number of all forms of aggregates and increase in monomers was observed due to the onset 
of the hook effect. The variation in results from assay to assay is lower using this analysis, 
than for the previous two examples for mean bead size and concentration. The reduction in 
variation is expected as the average population value is no longer being used, and therefore 
the small number of larger aggregates is not lost on the analysis. In addition if any particles 
are lost during the wash and MAS stages it does not impact upon the ratio between monomers 
and larger aggregates as the remaining fraction is examined rather than a raw concentration. It 
was assumed that an equal proportion of monomers and dimers would be lost during any 
washing stages; this may not hold true as larger aggregates tend to separate out from solution 
at faster rates. However, the reduction in errors bars and the mirroring of the dimer and 
monomer peak suggest that there was not a strong sample bias toward larger aggregates. This 
method is suggested as means to monitor particle aggregation, hence any following data was 
treated in the same way. 
5.4.2. Effect of magnetic assisted aggregation (MAS) and overcoming the hook effect 
Figure 5.3A presents the number of monomers as a function of analyte concentration and 
number of MAS performed. The influence of magnetic separation steps on the assay itself 
was determined by analysing the number of monomers with and without the MAS.  Several 
observations could be made from these results, firstly in the absence of the MAS (red curve) 
fewer aggregates appeared to form, and the number of monomers was high across the range 
of analyte concentrations. Without the application of a magnetic field aggregates are only 
formed if two beads collide with the correct orientation and alignment to form a bond. Upon 
the addition of the magnetic field the number of interactions increased, leading to an increase 
in aggregation and a greater decrease in the number of monomers. When the number of MAS 
stages was increased from 2 to 4 the number of monomers across the concentration range did 
not decrease dramatically, suggesting that 2 MAS steps was sufficient to increase aggregate 
formation.  
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Figure 5. 3: A Effect of the number of magnet assisted aggregation stages (MAS) on the distribution of 
monomers for the reaction conditions using 5 x 10
8
 beads/mL of 3 µm avidin modified beads 25 minutes assay 
time, binding capacity 14 µg/mg. B Under the same bead conditions as A, effect of the addition of more beads 
during the MAS. Red = monomer, Green = Dimer, Blue = trimer and purple = tetramer.  
The hook effect could be problematic during an analytical measurement as two 
concentrations of analyte could produce the same aggregation ratio. To explore the possibility 
of removing the hook effect, a second aliquot of beads was added to the solution after the first 
MAS stage. The MAS stage was repeated two more times and the sample analysed. Figure 
5.3B displays the results and the fraction of the sample that was measured to be mono-, di-, 
tri- and tetra-mers. It is clear from figure 5.3B that the characteristic decrease in aggregate 
signal and increase in monomer signal typically observed at high concentrations of analyte 
was no longer present, and a gradual decrease in monomer signal is observed across the entire 
range of the assay suggesting that the hook effect had been overcome. The explanation for 
this is that at high concentrations of analyte the majority of the binding sites on the beads are 
occupied. Therefore when brought into contact with each other no free binding sites exist to 
form aggregates. The addition of fresh beads after the first MAS stage introduces vacant 
binding sites leading to aggregation.   
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5.4.3. Effects of binding capacity, bead concentration, and diameter 
To further investigate the sensitivity of the assay, a set of experiments was devised in which 
the binding capacity was systematically varied. Figure 5.4A and B present the percentage of 
monomers and dimers, respectively, produced by the interaction of 3 µm SPBs across a range 
of analyte concentrations for 4 different binding capacities.  In each experiment the binding 
capacity of the beads was gradually decreased from 14 µg/mg to 3 µg/mg. As the binding 
capacity is lowered, the intensity of the monomers and dimers signal decreased. Hence as the 
binding capacity is reduced the beads are less efficient at forming aggregates and therefore 
the signal is diminished.  
 
Figure 5. 4: Distribution of monomers A, and dimers B, for the reaction conditions using 5 x 10
8
 beads /ml of 3 
µm avidin modified beads. The binding capacity, displayed in the legend in terms of µg/mg of beads was varied 
and the intensity of change in aggregate size plotted as a function of analyte concentration.   
Figure 5.5A illustrates the effect of lowering the number of beads in the assay, and thus 
reducing the total number of binding sites. This had the effect of shifting the onset of the 
hook effect to a lower concentration as the total number of binding sites in solution are 
saturated at lower concentrations. Whilst the hook effect appears earlier at a lower analyte 
concentration it is also worth noting that the maximum decrease in monomer signal is also 
shifted to a lower analyte concentration, effectively boosting the sensitivity. The onset of the 
hook effect was found to be closely linked to both the concentration of avidin in the reaction 
and the density of avidin on the beads.  
To test the effect of particle size a similar set of experiments were then performed with 
biotinylated-BSA for avidin functionalized 1 µm beads and the results from this are shown in 
figure 5.5B. Qualitatively, similar trends were observed when changing the concentration of 1 
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µm beads as previously observed for the 3 µm beads hence, both the intensity and position of 
the maximum number of aggregates can again be tailored by changing the bead number and 
binding capacity. Quantitatively, however, the results for the 1 µm beads differed from the 3 
µm beads.  It is clear from figure 5.5B that when a similar concentration of beads is used for 
the two bead sizes (green and blue curves) the peak in aggregation appeared at much lower 
concentration of analyte for the 1 µm beads and a much larger fraction of beads formed 
aggregates. The interpretation of this result is that when the same number of 1 and 3 µm 
beads are used the 1 µm beads aggregate more efficiently. This is most likely due to the fact 
that the 1 µm beads have a higher rotational diffusion coefficient. When the binding capacity 
of the beads were matched i.e. more 1 µm beads were added to solution (blue and red curves) 
the onset of the hook effect again is shifted to higher concentrations of analyte, reflecting the 
change in total binding capacity of the beads surface.  
 
Figure 5. 5: A Effect of concentration of beads upon maximum decrease in monomer signal using 3 µm avidin 
modified beads, binding capacity of 14 µg/mg, 25 min assay time and 5 x 10
8
 beads /mL  = red, 2.5 x 10
8
 beads 
/mL  = purple, 1 x 10
8
 beads /mL = blue, and 1 x 10
7
 beads/mL  = orange. Highlighted on the graph is the 
minimum in each curve for the dilutions.  B Effect of concentration of beads upon maximum decrease in 
monomer signal, 25 min assay: 3 µm avidin modified beads 5 x 10
8
 beads /mL, binding capacity 14 µg/mg = 
blue, 1 µm avidin modified beads, 6 x 10
9
 beads /mL, binding capacity 20 µg/mg  = red, and 1 µm avidin 
modified beads, 5 x 10
8
 beads /mL binding capacity 20 µg/mg = green. 
An interesting deviation in the behaviour of the 1 µm compared to the 3 µm beads arises in 
the fact that the trimers behave in a comparable manner to that of the monomers, i.e. the peak 
in trimer concentration best matches the dip in monomers, figure 5.6A, whereas for 3 µm 
beads a decrease in monomers is most closely correlated with an increase in dimers as 
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demonstrated in figure 5.6D. It is not immediately clear why there should be a preference for 
trimers.  
 
 
Figure 5. 6: A Distribution of monomer = red, dimer = green, trimer = blue and tetramer = purple. 1 µm avidin 
modified beads 25 min assay time 6 x 10
9
 beads /mL, binding capacity 20 µg/mg. B Distribution of monomer = 
red, dimer = green, and tetramer = purple using 0.3 µm Streptavidin modified beads 25 min assay time 1 x 10
10
 
beads /mL, binding capacity 4 µg/mg. C Distribution of 5mer = blue, 6mer = purple, and 7mer = green and 
8mer = Red using 0.3 µm Streptavidin modified beads 25 min assay time 1 x 10
10
 beads /mL binding capacity 4 
µg/mg. D Correlation between the increase in aggregate size versus the decrease in monomer signal for the three 
different bead sizes.  
 
To further investigate the relationship between bead size and aggregate size a smaller 300 nm 
bead functionalised with streptavidin was added to the target analyte. In these assays a 
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comparable binding capacity was used. The results of this assay are displayed in figures 5.6B 
and C. In figure 5.6B the change in monomer, dimer and tetramer are plotted as a function of 
analyte concentration, a similar trend in monomer is observed and the numbers decrease as 
the analyte concentration increases. Unlike the larger 3 µm particles, the dimers in solution 
showed no correlation with the monomers and instead the larger tetramers mirrored the 
monomer relationship. Figure 5.6C plots the larger 5-, 6-, 7- and 8-mers versus concentration 
and whilst their signal intensity is weak they show good agreement with the decrease in the 
proportion of monomers in the analysed population.  
The correlation between monomers and the larger aggregates was plotted for the 3, 1 and 0.3 
µm diameter beads as illustrated in figure 5.6D. For the larger 3 µm beads a strong 
correlation was observed between the monomers and the di-, tri- and tetramers in solution. As 
the beads diameter decreased the correlation between the monomer and dimer decreases from 
0.96 to 0.5 and 0.2 for the 3, 1 and 0.3 µm beads respectively. When using the smaller 0.3 µm 
particles there was a good correlation between 3-5mers and 9-11mers with the decrease in 
monomer concentration. In these experiments the smaller particles were clearly more 
efficient at forming larger aggregates, and one possible explanation is that the smaller beads 
have an ability to nucleate and grow in aggregate size, mimicking crystallization of 
nanoparticles. Micron sized particles have previously been used as model systems to aid with 
nucleation and growth studies
7,8
. Similar observations of cluster size might have proven 
difficult using flow cytometry or light scattering techniques and the TRPS may offer the 
possibility of studying the aggregation and growth of colloidal particles in solution because 
unlike other systems it is possible to get information regarding the individual clusters rather 
than an average and an assumed normal distribution.  
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5.5. Conclusion 
TRPS was used to characterise the aggregation of avidin functionalized particles in the 
presence of a biotinylated target. Several methods for data interpretation, aimed at increasing 
the reproducibility of the experiment and allowing for a detailed and informative study of the 
aggregation state, were discussed. Further, TRPS technology was used to investigate key 
experimental variables in designing a magnetic aggregation assay. A summary of all the 
factors that were found to influence the sensitivity of the assay can be found in figure 5.7. 
The resulting assay platform was capable of operating over several orders of magnitude of 
concentration; the sensitivity of the assay could be improved upon by increasing the density 
of receptors on the beads, decreasing the size of the beads used, and/or decreasing the total 
number of beads used in the assay.  However, higher sensitivities occasionally resulted in a 
more rapid saturation of the beads with analyte and thus earlier onset of the hook effect. By 
controlling the particle size, binding capacity, and particle concentration, the aggregation of 
SPM beads in the presence of the target analyte could be tailored and predicted to produce a 
simple and sensitive analytical method. We also note that for smaller particles it may be 
possible to monitor the increase in the larger 9-11mer particle aggregates and utilize their 
frequency to follow the analyte concentration.  
 
Figure 5. 7: Summary schematic of the changes in monomer population related to physical properties of the 
SPM beads. 1: reference curve, 2: decrease binding capacity (B), 3: decrease concentration (V), 4, decrease bead 
radius (r). 
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Chapter Six 
Multiplexed detection of growth factors with TRPS 
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6.1. Abstract 
Diagnostics that are capable of detecting multiple biomarkers can improve the accuracy and 
efficiency of bioassays. In chapter 4 the potential of an aptamer-based sensor (aptasensor) 
utilising Tunable Resistive Pulse Sensing (TRPS) was demonstrated. Here, the technique is 
advanced towards identifying key experimental designs for multiplexed TRPS aptasensor 
assays. The assay utilised superparamagnetic beads, and using TRPS monitored their 
translocations through a pore. If the surfaces of the beads are modified with an aptamer, the 
frequency of beads (translocations/minute) through the pore can be related to the 
concentration of specific proteins in the solution. In this chapter TRPS was used to observe 
the binding of two proteins to their specific aptamers simultaneously. A series of experiments 
are described illustrating key factors which are integral to bead-based assays and demonstrate 
a general method for a multiplexed assay. In summary, the effects of bead size, concentration, 
potential bias, pH and aptamer affinity to enhance the sensitivity and practically of a TRPS 
aptasensor have been explored. The method utilises the fact the binding of the aptamer to the 
protein results in a change in charge density on the bead surface, the isoelectric point of the 
protein then dominates the mobility of the beads. By alteration of the applied potential to the 
instrument it is possible to produce a positive signal in a simple multiplexed assay. 
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6.2. Introduction: 
As highlighted in chapters 3 and 4 TRPS is well suited to detect DNA and DNA-protein 
interactions; previous work has provided proof-of-concept studies on the technology in which 
the velocity and frequency of aptamer-tagged beads changes upon the addition of the target 
analyte as the aptamer folds to a specific conformation whereby the target binds, shielding 
the surface charge and altering double layer structure, as has been demonstrated with the 
target thrombin. A significant development to this method would be the ability to detect 
multiple proteins at once. 
Building upon the foundations set in the previous chapters, this chapter is focussed around 
the development of a multiplexed aptasensor to the haemostatic growth factors Vascular 
Endothelial Growth Factor (VEGF) and Platelet Derived Growth Factor (PDGF). In normal 
physiology these growth factors regulate the growth of new blood vessels, however certain 
disease states, such as those in cancer, hijack these pathways to increase blood supply for 
tumour growth. As such both proteins are involved in various disease processes such as 
cancer
1
, atherosclerosis
2
, and Alzheimer’s3 and could be potential biomarkers for the 
diagnosis and monitoring of these diseases. Although circulating levels of VEGF have been 
found to be variable between individuals, between 9 – 150 ng/L4, VEGF levels have been 
demonstrated to be elevated in several aggressive types of cancer, such as ovarian
5
, 
haematoloical
6
 and gastric carcinoma
7
 and VEGF measurement has been highlighted as both 
a potential prognostic or diagnostic marker
4
 and for comparison between pre- and post-
operative cancer states
5,7
. PDGF levels have also been found to be elevated in several 
different forms of cancer and has recently been added to the Glasgow Prognostic Index, 
which measures inflammatory mediators, as an important indication of tumour and significant 
predictor of survival
8
. Previous studies have measured both VEGF and PDGF levels in cancer 
patients undergoing anti-VEGF treatment
9
, however this was performed over two different 
systems, increasing the cost and time considerations of the assay. 
To monitor two analytes simultaneously in one-step analysis the ability of TRPS to provide 
accurate particle-by-particle analysis was utilised. The ability of TRPS to accurately calculate 
the size of individual objects as they traverse the pore was exploited and allows the data from 
each particle set to be separated according to their size. By using two differently sized beads 
and separately functionalising them with anti-VEGF or anti-PDGF aptamers, as displayed in 
figure 6.1A, it is possible to separate the individual signals based on Δip, figure 6.1C, and 
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monitor changes to their frequency and speed, relating them back to the target analyte 
concentration.  
 
Figure 6. 2: A Schematic of the multiplexed experimental process; two beads of different sizes are conjugated 
to either VEGF or PDGF. B Beads are incubated with a combination of concentrations of VEGF and PDGF for 
30 minutes; as they bind to the target their velocity and frequency through the pore is monitored. C Recorded 
“resistive peaks” for two different sized beads; the blockade magnitude (Δip) of each peak is proportional to the 
volume of each bead and can therefore be calibrated to provide the diameter of each individual bead. 
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6.3. Method: 
6.3.1. Chemicals and reagents 
The following chemicals were sourced from Sigma Aldrich, UK, without any further 
purification unless otherwise stated: Phosphate Buffered Saline (PBS – P4417), Tween 20 
(P1379), Bovine Serum Albumin (BSA – A2153), and thrombin (T7513). DNA sequences 
were obtained from Sigma Aldrich’s custom oligonucleotides service as lyophilised powders 
and made up to a stock concentration of 100pmol/µL: 5’ CAG GCT ACG GCA CGT AGA 
GCA TCA CCA TGA TCC TG-Biotin-3’ (anti-PDGF-BB aptamer)10, 5’ ATA CCA GTC 
TAT TCA ATT GGG CCC GTC CGT ATG GTG GGT GTG CTG GCC AG-Biotin-3’ 
(VEa5 anti-VEGF aptamer)
11. 5’ TGT GGG GGT GGA CGG GCC GGG TAG ATT TTT-
Biotin-3’ (V7t1 anti-VEGF aptamer)12. Human recombinant PDGF-BB and human VEGF165 
were purchased from Life Technologies, UK (PHG0044 and PHC9394, respectively). Water 
purified to a resistivity of 18.2 MΩ cm (Maxima) was used to make all solutions unless 
otherwise specified. 
Streptavidin modified superparamagnetic beads of 120 nm (bio-adembeads streptavidin plus 
0321) and 300 nm (bio-adembeads streptavidin 0313) in diameter were purchased from 
Ademtech (France). Binding capacities of 120 nm and 300 nm beads according to the 
manufacturer were 3512 pmol/mg and 477 pmol/mg respectively. Carboxyl beads of known 
concentration and diameter (SKP200; mode diameter 200 nm) were sourced from Izon 
Sciences (Oxford, UK) to be used as a calibrant. All bead dilutions were performed in 
1xPBST (0.05% Tween). 
6.3.2. Aptamer functionalisation 
The 120 and 300 nm beads were vortexed for 1 minute, sonicated for 1 minute and diluted to 
a concentration of 3 × 10
9
 beads/mL in PBST. The streptavidin coated beads were incubated 
with a 10-fold excess above the manufacturer specified binding capacity of the desired 
biotinylated aptamer at room temperature on a rotary wheel for 30 minutes to allow the 
streptavidin to react with the biotinylated ends of the DNA. The functionalised beads were 
then removed from the rotary wheel and centrifuged for 2 minutes at 10 000 rpm before being 
placed onto a MagRack (Life Sciences). After 2 minutes the beads had formed a visible 
cluster in the sample vial adjacent to the magnet and the solution was carefully removed and 
replaced with an equal volume of PBST – this wash stage was performed twice to remove 
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any excess aptamer which would lower the sensitivity of the binding assay. These could then 
be stored in the fridge. 
6.3.3. Protein measurement 
6.3.3.1. Individual protein measurement 
Either 120 nm or 300 nm beads functionalised with the aptamers were divided into several 
vials at a concentration of 3 × 10
9
  beads/mL, to which varying volumes of either PDGF-BB 
or VEGF165 stock solution was added to each vial to create samples of aptamer modified 
beads mixed with a range of protein concentrations. In all cases the volume of the solution 
was adjusted and kept constant by adding PBST. Each sample was left on a rotary wheel for 
30 minutes to allow the protein to associate before being introduced into the TRPS 
instrument.  
6.3.3.2. Multiplexed protein measurement 
120 nm beads with V7t1 aptamer and 300 nm beads with PDGF-BB aptamer were prepared 
as described above in section 6.3.2. at a bead concentration of  6 × 10
9
 beads/mL. 16 samples 
containing 50 µL of 120 nm beads and 50 µL of 300 nm beads were prepared, and 
combinations of concentrations of PDGF-BB and VEGF165 were added. Each sample was left 
on a rotary wheel for 30 minutes to allow the protein to associate before being introduced into 
the TRPS instrument. Each sample was analysed via TRPS for the maximum run time of 10 
minutes. The peak traces were calibrated and separated according to their size for 
independent analyses. Each individual blockade trace was examined for shape and 
directionality before being included in the sample set.  
6.3.4. Tunable Resistive Pulse Sensing (TRPS) measurement 
Measurements were made with the Izon qNano system, purchased from Izon Sciences 
(Oxford, UK) which incorporates the fluid cell, stretching apparatus, data recording and 
analysis software (Control Suite V2.2.2.117). The pores used were designated “np200” by the 
manufacturer and are described as most suitable for detecting beads in the range 100 – 300 
nm. A stretch of 46 mm and voltage of +/-0.4 V were chosen so that blockade events were 
clearly visible above the level of noise (<10pA); these conditions were maintained 
throughout the experiments so that data was comparable. 80µL of electrolyte buffer (PBS) 
was carefully pipetted into the lower fluid cell, taking care not to introduce bubbles. The 
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upper fluid cell was then attached to the instrument and 40 µL of PBST was added to enable 
confirmation of a stable baseline and clean pore. When a positive current is applied (+0.4 V) 
peaks are visible as a downward deflection from the baseline, when a negative current is 
applied (-0.4 V) peak were visible as upward deflections of the baseline.  
6.3.5. Data Analysis 
6.3.5.1. Removal of reverse peaks 
Raw data was analysed by examining each individual blockade trace visually using the Izon 
ControlSuite V2.2.2.117 Software. When resistance was highest at the beginning of this peak 
and tailed toward the baseline with time this was considered a “normal” translocation. When 
the current increased gradually and then dropped sharply this was considered a “reverse” 
translocation and removed from subsequent data processing. Examples of these are shown in 
figure 6.3. 
6.3.5.2. Extraction of particle rate for each bead population 
Each bead records a blockade magnitude that reflects its volume, for example 120 nm 
Ademtech beads typically produce a blockade magnitude of 0.17 nA with the pore setup used 
here. Data which had been visually inspected as described above were then calibrated with 
beads of known diameter and narrow distribution. Prior to any analysis the Ademtech beads 
were calibrated separately to accurately measure the range of particle sizes in the provided 
batches and these ranges were used to provide filter information for data processing of 
experimental samples. Peaks recorded as being between 100 and 200 nm were recorded as 
“120 nm” and peaks between 210 and 400 nm were recorded as “300 nm”. Data was then 
extracted as a .csv file containing data for each particle and the particle rate was then 
calculated by counting the number of beads observed divided by the recording time.  
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6.4. Results and Discussion: 
6.4.1. Detection of VEGF165  under positive bias 
The goal of the final assay was to detect both VEGF and PDGF simultaneously. Firstly, it 
was important to confirm that the interaction of the chosen aptamers and proteins did create a 
measurable signal, similar to that observed in chapter 4. Typically anti-VEGF aptamers were 
immobilised onto 120 nm beads and anti-PDGF aptamer was immobilised onto 300 nm beads 
as portrayed in Figure 6. 2.  
Initially the TRPS instrument was set up with a positive bias applied to the electrode under 
the nanopore (lower fluid cell) similarly to that used in chapters 3 and 4. Samples containing 
120 nm beads functionalised with VEa5 anti-VEGF aptamer were prepared and incubated 
with several concentrations of VEGF165. These samples were then recorded via TRPS, with 
the resultant data displayed in Figure 6. 3A. It was expected that the rate would diminish with 
increasing protein concentration, as had been previously observed for the thrombin protein 
for the similar experimental design discussed in chapter 4 due to the protein binding the 
Figure 6. 3: scatter plots displaying average rate for 120 nm bead functionalised with VEa5 (A) and V7t1 (B) 
aptamers against concentration of VEGF165 under an applied positive bias. 
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aptamer and shielding the negative charge of the phosphate backbone. As the concentration 
of VEGF165 was increased from 0 to 10nM the predicted decrease in particle rate was 
observed, however at higher concentrations, > 10nM, the particle rate increased before 
reaching a steady value of ~220 beads per minute.  The current traces were examined in more 
detail and observed numerous double peaks, shown in Figure 6. 4. The tunable conical pore 
used in TRPS gives rise to a characteristic peak shape, displayed in Figure 6. 2 and Figure 6. 
4 and explained in detail in chapter 2 and elsewhere
13
. The shape of the peak provides 
information on the direction in which the particle is travelling. For beads travelling from the 
top of the fluid cell entering the narrow sensing zone first before then traveling through the 
pore into the expanding conical region they produce a peak shape  as shown in Figure 6. 2 
and Figure 6. 4. If a particle were to travel in the reverse direction the peak shape would be 
inverted Figure 6. 4. Below 10 nM no reverse peaks were observed throughout the 
experiment, however when the concentration of VEGF increased, > 10 nM, there was an 
increase in the number of peak traces, termed “reverse peaks” which represent beads coming 
back up from the base of the pore. The presence of these reverse peaks led to an increase in 
the rate recorded by the software which does not distinguish between the peaks based on 
direction of travel. When these erroneous peaks were then removed from the data set, the rate 
diminished, as expected, with increasing VEGF165 concentration, as shown in Figure 6. 5.  
Figure 6. 4: Example blockade traces indicative of forward (left) or reversed (right) travel through the pore 
under a positive (top) or negative (bottom) bias. 
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To confirm that this effect was not the result of a specific mechanism between VEa5 and the 
heparin binding domain (HBD) of VEGF165
11
 this experiment was repeated with a second 
aptamer, V7t1, which binds away from the HBD to the receptor binding domain (RBD) by 
forming a g-quadruplex
12
. For V7t1 the same effect was observed as displayed in Figure 6. 
3B. Both of these aptamers produced reversed peaks at higher analyte concentrations and 
provide evidence that this observation was not due to a specific aptamer-epitope interaction. 
For V7t1 this reversal occurred at lower concentrations of VEGF165 due to the higher affinity 
of the aptamer. Previous thrombin data from chapter four was re-examined by individual 
blockade traces and no reverse peaks were observed. 
6.4.2. Detection of PDGF-BB under positive bias 
In a typical TRPS experiment it has been shown that the number of bead translocations is a 
function of the bead concentration, diffusion coefficient of the beads, applied pressure, 
electroosmotic and electrophoretic mobility as discussed in chapter 2, and expressed in 
equation 2.9. Thus, within the current experimental setup, ensuring concentration, pressure 
and osmotic contributions remain constant, changes in particle translocations were inferred to 
be due to a change in the electrophoretic mobility of the beads. The observation of the beads 
re-entering the pore and moving from the lower fluid cell back up to the upper was attributed 
to the addition of the protein and its charge. VEGF165 has a reported isoelectric point at pH 
8.5
14
, suggesting that at the pH of the chosen electrolyte buffer, 7.4, the protein should have a 
Figure 6. 5: Scatter plot displying average rate for 120 nm beads functionalised with VEa5 following filtering 
for reversed peaks, n = 3. 
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net positive surface charge, whereas thrombin (pI 7.1
15
) would be largely neutral. Upon 
binding to the aptamer and shielding the phosphate backbone the charge upon the protein 
must therefore dominate the electrophoretic mobility. As this occurred with both VEGF 
aptamers, which as stated above bind to different regions of the protein, it does not seem to 
affect the results  which epitope is occupied.  
These experiments were then repeated using 300 nm beads functionalised with anti-PDGF 
aptamer and increasing PDGF-BB concentrations to explore whether the same effects would 
be observed and to confirm that PDGF-BB binding also produced a measurable signal for 
detection. Firstly, a positive bias was applied to the lower fluid cell of + 0.4 V, and a 
diminution of particle rate was observed as PDGF concentration increases as displayed in 
Figure 6. 6A. Unlike within the VEGF experiment where beads were observed translocating 
the pore in reverse i.e. from the lower fluid cell to the upper, no reverse peaks were observed. 
To ascertain if this effect was dependent upon the bead size i.e. due to additional mass of the 
300nm beads creating bias given the larger gravitational forces, the same experiment was 
performed using 120 nm beads. Again no reverse translocations were observed suggesting 
that gravitational effects did not impact upon this measurement. The same trend was observed 
and is displayed in Figure 6. 6B, confirming that the lack of reversed peaks is not an artefact 
of using a different bead size. As PDGF-BB has an isoelectric point of 9.8 it is assumed that 
the protein would have a positive surface charge in the chosen electrolyte. The absence of 
reversed translocations, is then attributed to a mechanistic difference in the way that the 
protein is bound to the aptamer, for example the aptamer could be folded around the protein 
so that the charge of the phosphate background is not fully shielded.  
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Figure 6. 6: Particle rate against PDGF-BB concentration for 300 nm (A) and 120 nm (B) beads fuctionalised 
with anti-PDGF aptamer under posistive bias. 
6.4.3. Detection of VEGF165 and PDGF-BB under negative bias 
To test the hypothesis that the surface charge of the beads had become positive, the applied 
voltage bias was switched to a negative value (negative electrode, in the lower fluid cell). In 
this configuration DNA modified beads usually do not traverse the pore opening, or have a 
much reduced frequency of translocation, here for the 120nm particles no translocation 
events were recorded. Upon incubation with the VEGF protein the frequency of beads was 
directly proportional to the concentration of the protein, shown in Figure 6. 7. This is a major 
improvement and observation from previous thrombin work
16
. In thrombin studies the 
number of translocation events per minute decreases as target analyte concentration 
increased, in effect switching off the signal. Here we have a more typical and convenient 
setup, wherein an increase in analyte concentration produced an increase in signal.  
To determine if the bead size and concentration would have any impact on the sensitivity and 
ease of the assay we investigated their effects using the VEGF aptamers VEa5 and V7t1. 
Data summarising the effects of bead diameter and concentration are displayed in Figure 6. 
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7A and B. To investigate the effect of bead concentration VEa5 modified beads at 3, 2.5 and 
2 × 10
9
 beads/mL were added to solution containing the VEGF protein (Figure 6. 7A/B 
curves 2, 3 and 4). As the bead concentration decreases, so does the concentration of VEGF 
at which the bead rate remains constant 100 nM (line 2) to 25 nM (line 4), this has an impact 
upon the dynamic range of the assay and is likely due to a decrease in the number of available 
binding sites in solution, leading to the saturation of each individual bead with VEGF at 
much lower concentrations of protein. As indicated above the number of beads moving 
through the pore is proportional to their concentration, hence lower concentrations of beads 
will result in a lower overall rate, at bead concentrations below 2.5 × 10
9
 beads/mL it could 
be suggested that the bead count is so low (<10 beads a minute) it is no longer practical for 
accurate measurement and lengthens the required assay run-time unnecessarily.  
Figure 6. 7: A Average rates against VEGF165 concentration for (1)  3 × 10
9
  beads/mL 300 nm beads, (2) 3 × 
10
9
   beads/mL 120nm beads, (3)  2.5 × 10
9
  beads/mL 120 nm beads and (4) 2 × 10
9
   beads/mL 120 nm beads 
all functionalised with VEa5 aptamer. B Expanded view of highlighted area in A. C Average rates against 
VEGF165 concentration for 3 × 10
9
  beads/mL 120 nm beads functionalised with either (2) VEa5 or (5) V7t1 
aptamer. D Expanded view of highlighted area in C. For all data sets n = 3. 
To investigate the impact of bead size, the bead concentration was kept the same (3 × 10
9
 
beads/mL) and the diameter was increased to 300 nm (Figure 6. 7A and B line 1 and 2). The 
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rate of 300 nm beads at 0 nM VEGF was initially higher than the 120 nm beads with average 
rates of 35 and 0 beads/min respectively. It is likely that this is due to both the increased mass 
of the beads, leading to a higher gravitational effect, and also due to a lower relative loading 
of DNA per area of beads suspended. Both beads have comparable binding capacities (see 
method section) therefore we conclude the 300 nm beads have a lower packing density of 
streptavidin, and therefore DNA, on their surface.  
The differences in packing density might also be responsible for the differences in rate signal 
between 120 and 300 nm beads. It is observed that there is a sharp initial increase in rate 
upon addition of VEGF and the rate signal appears to saturate sooner for the 300 nm beads; 
this could indicate that the sensitivity could be tailored by altering the packing density of 
capture probe on the surface of beads. For the purposes of this assay, these results 
demonstrate that the 300 nm beads are able to provide a rate-related signal change in 
response to protein binding which can be analysed via TRPS, further supporting the notion of 
the multiplexed assay.  
Figure 6. 7C represents the difference in the rate signal for two anti-VEGF aptamers: VEa5 
(line 2) and V7t1 (line 5). There are two observations from this data; firstly, the rate signal 
for the V7t1 aptamer increases at low concentrations of VEGF and appears to have levelled 
out by 10 nM, whereas the rate of VEa5 beads continues to increase up to 100 nM of added 
protein. Initially we explored the same VEGF concentrations for both aptamers, however due 
to the rate remaining constant for the V7t1 aptamer at concentrations of VEGF > 1nM we 
chose to significantly reduce the amount of VEGF added. To illustrate this effect, Figure 6. 
7D displays an expanded view of the data for the V7t1 aptamer which exemplifies the ability 
of this aptasensor to detect VEGF at concentrations down to 0.05 nM. This is due to 
differences in aptamer binding mechanism and affinity. VEa5 has a reported KD of 130 nM
11
 
and is postulated to bind due to the presence of stem-loop structures
17
. V7t1 has a reported 
KD of 1.4 nM for VEGF165 and due to its lack of selectivity over VEGF121 is postulated to 
bind the receptor binding domain present on both VEGF analogues by forming a G-
quadruplex
12
; the superior affinity of V7t1 allows for the measurement of smaller 
concentrations of VEGF165 on this platform.  
The second observation from Figure 6. 7C is the marked difference in maximum rate between 
VEa5 and V7t1 which reach circa 60 beads/minute and 120 beads/minute, respectively at 
higher VEGF concentrations. As the overall number of aptamer molecules and beads should 
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be the same, the difference in rate must be due to the difference in length of DNA. As 
demonstrated in chapter 3, in addition to the concentration of DNA added to the beads 
surface, the length of DNA sequence used is also a key factor in determining the maximum 
bead rate through the pore
16
. The V7t1 aptamer is 20 nucleotides shorter than VEa5 and with 
a negative bias under the pore, and the concentration of the beads being identical in all 
experiments the rates vary ~40 beads/minute (V7t1) and ~1 bead/minute (VEa5) respectively, 
when VEGF concentration is 0 nM. This is attributed to the effects of the length of the DNA, 
with the short DNA sequence able to pass through the pore more easily. Upon the protein 
binding to the aptamer, we believe there are two possible reasons for the higher total rate for 
the shorter aptamer sequence. The first could be due to the protein shielding the phosphate 
backbone to a greater extent for the shorter DNA, and secondly the binding mechanism. The 
conformation of the DNA aptamer, the location it holds the protein with respect to the bead, 
could impact on the bead zeta potential and drag, however further work is needed to infer 
implications of any mechanistic differences. 
To further support the theory that bead rate is dominated by the charge of VEGF, the pH of 
the electrolyte buffer was adjusted to pH 9.3. It was expected that at this pH the VEGF would 
have an overall slightly negative surface charge, and with a negative voltage bias applied 
under the pore the previously observed increase in particle rate with increasing protein 
concentration would be eliminated. As shown in table 1 this was indeed found to be the case, 
with bead rate remaining at 0.5 beads/min. 
When the applied potential was reversed to an equal positive potential, the rate decreases 
with increasing protein concentration, reverting back to the trend observed previously with 
thrombin
16
, i.e. a diminution, suggesting a charge-shielding mechanism is taking place.  
Table 6. 1: comparative summary of the effect of buffer pH on recorded particle rate using the same pore and 
instrument conditions. 
In order to confirm that the two bead populations and their respective proteins could be 
analysed together under the same conditions, experiments were then performed for PDGF-BB 
under a fixed negative bias of -0.4 V. Figure 6. 8 displays the results for these experiments in 
which a clear and proportional increase in rate is visible with increasing PDGF 
 Rate (beads/min) 
 Negative bias (- 0.4 V) Positive bias (+ 0.4 V) 
[VEGF] (nM) pH 7.4 pH 9.3 pH 7.4 pH 9.3 
0 1.6 0.5 150 165 
100 68 0.5 40.8 90 
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concentrations. As the behaviour of PDGF and VEGF bound beads was found to be similar, 
providing an increase in rate under a negative bias, it can be concluded that both proteins can 
be observed binding their aptamers under these conditions.  
 
Figure 6. 8: particle rate against PDGF-BB concentration for 300 nm beads functionalised with anti-PDGF 
aptamer under negative bias. 
6.4.4. The impact of aggregation on detection of PDGF-BB 
PDGF-BB is a homodimeric protein, as such, one might expect to see aggregation as 
aptamers on two beads can interact with the same protein molecule, as has been observed in 
some assays previously
18
. To investigate this, the blockade magnitude was analysed. A plot 
of blockage magnitude against PDGF-BB concentration is plotted in figure 6.8 below. It is 
observable that there is an initial sharp increase in magnitude up to a concentration of 10 nM 
PDGF-BB, suggesting that in these experiments aggregates are formed as the volume of each 
entity passes through the pore is increased. The mean blockade magnitude decreases after this 
initial increase, this may be attributed to the hook effect described in chapter five as the 
number of PDGF-BB proteins increases, saturating the available binding sites.  
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Figure 6. 8: Mean blockade magnitude against PDGF concentration for 300 nm beads functionalised with 
PDGF aptamer with negative bias; error bars represent 1 standard deviation from the mean. 
The range of Δip values (nA) which were observed as monomeric beads passed through the 
pore after sonication and without any PDGF-BB was used as a bin size and the size of 
aggregate determined as described previously in chapter five. The percentage of particles 
traversing the pore which were monomers was then determined, the results for which are 
displayed in figure 6. 9 below. As reflected in figure 6. 8 above, the number of aggregates 
initially increases, and then decreases again, however, this method of examining the data 
reveals that there is not a complete hook effect, and that some aggregates remain throughout 
the concentration range. 
An increase in the number of aggregates could be problematic in rate based assays and more 
particles are clustered together and traversing as one, which should in theory cause a 
reduction in rate. However an increase in rate in relation to PDGF-BB concentration is still 
clearly visible, thus the formation of aggregates did not affect this method, suggesting that the 
aggregates formed were not large clusters and that the effect on the rate signal is negligible. 
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Figure 6. 9: A % of bead aggregates (i) or monomers (ii) against PDGF-BB concentration. B expanded view of 
A for 300 nm beads functionalised with PDGF aptamer analysed under negative bias. 
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6.4.5. Multiplexed detection of PDGF-BB and VEGF165 
In order to successfully multiplex the rate signals for two different bead sizes, it first must be 
possible to differentiate the beads from one another. Figure 6. 10A displays the calibrated 
diameter distributions for the two different bead sets measured separately and together (inset) 
which confirms that the resolution of TRPS is able to distinguish these two bead populations 
without overlap. The distribution of 120 nm bio-adembeads streptavidin plus (Figure 6. 10Ai) 
is much narrower than for the 300 nm bio-adembeads streptavidin; this is believed to be due 
to a difference in the stringency of bead manufacture – it is possible to see the distribution of 
bead diameters with great accuracy due to the particle-by-particle analysis of TRPS which 
has been shown to have far greater resolving power over conventional sizing techniques, such 
as Dynamic Light Scattering, when analysing non-uniform dispersions
19–21
.  
 
 
Figure 6. 10: A distribution of particle diameters for (i) 120 nm bio-adembeads streptavidin plus (ademtech, 
France) and (ii) 300 nm bio-adembeads streptavidin (ademtech, France). Inset is the distribution of particle 
diameters for a mixture of 120 and 300 nm beads.  B 1 combined rate of equal concentrations of 120 and 300 
nm beads passing through the pore, 2 rate of 120 nm beads taken from 1, 3 rate of 300 nm beads, taken from 1.  
Figure 6. B line 1 is an example of the raw data plot showing particle count versus time for a 
sample containing both 120 and 300 nm beads. Following the experiment the data was  
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Figure 6. 11: A bar graph comparing the average particle rates of 120 nm beads functionalised with V7t1 as 
VEGF165 concentration increases with or without the addition of 10 nM PDGF-BB in the presence of 300 nm 
beads functionalised with anti-PDGF aptamer. B bar graph comparing the average particle rates of 300 nm 
beads functionalised with anti-PDGF aptamer as PDGF-BB concentration increases with or without the addition 
of 10 nM VEGF165 in the presence of 120 nm beads functionalised with V7t1. Error bars represent the standard 
deviation from the mean of each individual calculated particle rate (n=>500 run time = 10 minutes). 
 
exported into excel, filtered by measured particle diameter, and the total bead count was 
separated into the two different beads sizes, lines 2 and 3. The 120 nm beads (line 2) are seen 
to run through the pore at a greater frequency than the 300 nm beads, despite being at the 
same concentration;  this has been attributed to the effect of the ratio of the diameter of the 
pore constriction vs the diameter of the beads. As the pore size is reduced the particle rate 
decreases
22
 and this will be seen to a greater extent for the larger 300nm beads. In these 
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experiments the size of the pore was not able to be increased any further to compensate for 
this as the signal from the smaller 120 nm beads would have been lost in the baseline noise.  
In order to multiplex the assay it is imperative to ensure that the presence of additional 
proteins and beads do not interfere with the signal. Figure 6. 11A shows the rate of 120 nm 
beads in the presence of different concentrations of VEGF with or without 10 nM PDGF-BB 
and Figure 6.  11B displays the rate for 300 nm beads with or without 10 nM VEGF165, in all 
these experiments the second bead was always present.  These observations confirm that a 
decrease in rate was still able to be observed for both bead sets interacting with their specific 
proteins in the presence of additional beads. An increase in rate was still visible for the 120 
nm beads regardless of the addition of 300 nm beads and PDGF-BB concentrations. As 
expected from Figure 6. 7, 6. 11A displays little difference between the values for 0.5 and 10 
nM of VEGF, suggesting that at this point all of the available binding sites on the 120 nm 
bead were occupied. 
In Figure 6. 11B it was observed that there was little difference between 2 and 7 nM of 
PDGF-BB, it was postulated that one individual homodimeric PDGF-BB molecule could 
interact with two aptamers on the surface of the beads, and that it is only when PDGF-BB 
concentration is increased significantly that surface coverage of PDGF-BB on the beads is 
sufficient to cause a large increase in rate. In the future this could be investigated by altering 
the concentration of aptamer on the surface of the beads and monitoring any change in 
sensitivity. 
The frequency of both bead sets was measured in the presence of several combinations of 
concentrations of PDGF-BB and VEGF165. The data from all of these experiments are 
represented as surface plots in Figure 6. 12A and B. For both bead sets (A and B) rate is seen 
to increase when their specific protein target concentration is increased. This trend remains 
largely unaffected by the presence of the other bead population and protein and the two can 
be measured independently.  
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Figure 6. 12: A 3D surface plot displaying the effect of PDGF and VEGF on particle rate of 120 nm beads. B 
3D surface plot displaying the effect of PDGF and VEGF on particle rate of 300 nm beads.  
These results suggest that the simultaneous measurement of two different growth factors by 
TRPS was possible by using differently sized beads to provide a signal which is able to be 
selectively filtered by blockade magnitude to pull out the desired individual rate data. The 
observed increases in particle rate are believed to be due to an increase in electrophoretic 
mobility toward the negative electrode at the base of the pore when the positive proteins bind 
selectively to their respective DNA aptamers via a conformational change. 
Multiplexing the TRPS method illustrates the potential for the platform to be used as a 
biosensor. As demonstrated in the previous work in chapter 4, the technique offers 
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comparable sensitivity and assay times when compared to Surface Plasmon Resonance 
techniques or flow cytometry platforms. The TRPS technique does not have the throughput of 
a modern flow cytometer but does offer an improved signal and resolution for sub 500nm 
particles, without the need for fluorescent labels. 
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6.5. Conclusion 
VEGF165 and PDGF-BB were successfully monitored binding to aptamer-laden beads of 120 
and 300 nm in diameter. By altering the applied voltage bias it was possible to generate a 
positive signal i.e. rate increases with increased protein concentration, representing a 
significant improvement in the signal described in chapter four. Furthermore, it is suggested 
that with a knowledge of the target protein isoelectric point, one could tailor the electrolyte 
pH to provide a positive signal for each target. The signals generated were able to be 
monitored in situ and also in tandem with both proteins measured independently from one 
another using the same sample. This assay used the beads themselves as a label, without the 
need for any additional identifiers such as fluorophores. Parameters regarding bead 
concentration and size were considered and a multiplexed assay undertaken.  
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Chapter Seven 
TRPS as a tool to monitor aptamer-analyte induced 
particle dispersion 
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7.1. Abstract: 
The basis of this aptasensor is the controlled dispersion of reporter nanoparticles in the 
presence of the target analyte, which is measured via Tunable Resistive Pulse Sensing 
(TRPS). Each analyte triggers the release of multiple nanoparticles from the original 
bead conjugate, and this amplified signal allows the detection of the analyte orders of 
magnitude lower than the previous thrombin assay detailed in chapter 4. 1 µm 
superparamagnetic beads (SPBs) were coated with anti-thrombin aptamers and 
incubated with non-magnetic beads coated with a partially complementary 
oligonucleotide. The aggregates were monitored by TRPS by both an increase in 
volume and a decrease in blockade frequency. Following the addition of the target 
protein the aptamer undergoes a conformational change, dissociating from the 
complementary oligonucleotides and causing the SPBs to release their non-magnetic 
particle payload. The number of released beads increases with the concentration of the 
protein. This method was sensitive enough to detect down to 100 fM concentrations of 
thrombin, three orders of magnitude lower than previous reports using TRPS.  
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7.2. Introduction: 
During previous work discussed in chapter 4, thrombin was detected down to 4 nM using 
aptamer modified beads and the TRPS based detection platform. Here an improved method is 
reported capable of detecting fM concentrations of thrombin protein. The change in 
sensitivity comes from altering the measured signal. Previously the protein concentration was 
measured by monitoring the protein-bead conjugate, and in this configuration several proteins 
covering the beads surface were required to produce a signal. In brief, this assay entailed 
anchoring the aptamer directly to one bead and directly measuring the relative change in 
mobility as the thrombin concentration increased. This approach, while a useful proof-of-
concept for the detection of proteins and for aptamer characterisation, involved measuring the 
diminution of signal with increased concentration of protein which leaves room for 
improvement by generating a positive signal.  
In this assay 1 µm SPBs, (DynaBeads MyOne Carboxylic Acid) were coated with amine-
terminated anti-Thrombin-15 aptamer (3’Amine-TTTTTGGTTGGTGTGGTTGG5’)1 and 
either 800nm or 400nm carboxyl beads (Izon Sciences, CPC800) were coated with an amine-
terminated complementary sequence to the aptamer (3’Amine-
TTTTTTTTTCCAACCACA5’) as illustrated in figure 7.1. 
Initially the two bead populations form aggregates through the formation of double-stranded 
DNA (dsDNA). Upon the introduction of the target protein the dsDNA structure is disrupted 
by the conformational change of the anti-thrombin aptamer, causing the dispersion of the 
aggregate. By using two bead populations, the SPM beads with the anti-thrombin aptamer are 
able to be removed from the solution by a magnet leaving the dispersed smaller particles for 
analysis. The concentration of smaller particles that are dispersed increases with increasing 
protein concentrations. Here each protein releases a particle from an aggregate producing 
more efficient ratio between protein and measurable signal. Upon dissociation from the 
aptamer the protein can then go on to disrupt another particle causing a signal amplification 
which provides the much increased sensitivity observed in this assay.   
Herein an assay is presented capable of producing a signal at concentrations as low as 100 fM 
with an improved methodology, representing a significant advancement in the development 
of aptamer-based TRPS assays.  
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Figure 7. 1: Schematic of assay principles (not to scale). A) 1µm SPBs are coated with thrombin aptamer 
(purple) and 400 (or 800nm) beads are coated with a complementary strand of DNA (green). Aggregates are 
formed as complementary DNA binds. B) With the addition of thrombin, the aptamer undergoes a 
conformational change and the complementary DNA is released. C) The SPBs are separated by use of a magnet, 
leaving the 400 or 800nm beads (the dispersant) released by thrombin in solution to be removed for 
concentration analysis.D) example blockades for an 800 nm bead (i), a dynabead (ii) and an aggregate (iii). 
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7.3. Method: 
7.3.1. Chemicals and reagents 
Phosphate Buffered Saline (PBS – P4417), Tween 20 (P1379), MES hydrate (M2933), 
Bovine Serum Albumin (BSA – A2153), and thrombin (T7513) were sourced from Sigma 
Aldrich, UK without any further purification unless otherwise stated. EDC (77149) was 
purchased from Thermo Scientific. 
DNA sequences were obtained from Sigma Aldrich’s custom oligonucleotides service as 
lyophilised powders and made up to a stock concentration of 100pmol/µL: 5’ GGT TGG 
TGT GGT GGT TTT TTT TTT[AmC3]3’ (Thrombin 15 aptamer with amine terminus) and 
5’ ACA CCA ACC TTT TTT TTT[AmC3]3’ (Complementary sequence to thrombin 15 
aptamer with amine terminus). Water purified to a resistivity of 18.2 MΩ cm (Maxima) was 
used to make all solutions unless otherwise specified and 1xPBST (0.05% Tween) was used 
as the buffer. 
Carboxyl beads of known concentration and diameter were sourced from Izon Sciences 
(Oxford, UK) to be used both as a substrate for DNA attachment and as a calibrant: SKP400 
(mode diameter 350 nm, concentration 7.5×10
11
 beads/mL); CPC800 (mode diameter 750 
nm, concentration 9.5×10
10
 beads/mL); and CPC1000 (mode diameter 910 nm, concentration 
5.5×10
10
 beads/mL). Superparamagnetic Dynabeads® MyOne™ carboxylic acid (650.12) 
were purchased from Invitrogen provided as 10 mg/mL concentration. 
7.3.2. EDC coupling chemistry 
Beads were diluted to the required concentration (typically ×10
11
 non-magnetic beads or ×10
9 
Dynabeads MyOne) in MES hydrate buffer adjusted to pH 6 to a total volume of 450 µL. 
EDC was made up to 10 mg/mL concentration in MES hydrate buffer. 50 µL of 10 mg/mL 
EDC was then added to the 450 µL of beads. 4.5 nmol of the required DNA sequence was 
then added and the beads were left on a rotary wheel at room temperature for 2 hours. 
Following the incubation, the bead solution was removed from the rotary wheel and 
centrifuged for 5 minutes at 13 400 rpm. Any liquid was carefully pipetted out and the beads 
were resuspended in 450 µL of PBST, vortexed and sonicated. This wash procedure was 
repeated 3 times. Concentration analysis on the beads was performed via TRPS as described 
below. For these experiments DynaBeads MyOne were coated with thrombin binding 
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aptamer (TBA) and CPC800s or SKP400s with a complementary sequence with a T spacer 
using the procedure described above.  
7.3.3. Aggregate formation 
To create aggregates, the Dynabeads MyOne coated with TBA and either CPC800 or 
SKP400 beads coated with a complementary sequence were incubated together in the 
following concentrations for 30 minutes: 
CPC800 assay: 1×10
9
 beads/mL Dynabeads MyOne and 7×10
9
 beads/mL CPC800 were 
diluted in PBST. 
SKP400 assay: 1×10
9
 beads/mL Dynabeads MyOne and 5.6×10
10
 SKP400s.  
The samples were then stored upright in a centrifuge tube for 24 hours in a fridge.  
7.3.4. Thrombin addition 
From stock serial dilutions of thrombin were carried out in PBST such that the same volume 
of thrombin would be added to each sample so as not to introduce a potential source of bias 
by diluting the beads. To each 100 µL sample prepared as described in “aggregate formation” 
2 µL of thrombin was added to give concentrations ranging from 0 – 10 pM thrombin. A 
protein-rich control was also conducted in 0.2 mg/mL BSA to test the effect of non-specific 
protein addition.  
Samples were then left to incubate at room temperature on a rotary wheel for 30 minutes 
prior to analysis. These samples were then purified by magnetic separation on a MagRack 
(GE life sciences, Buckinghamshire, UK). After 5 minutes on the MagRack a pellet was 
clearly visible on the side of the sample vial adjacent to the magnet and the supernatant 
containing any remaining non-magnetic beads was carefully removed to a fresh vial for 
concentration analysis. Any further dilutions that were required were then carried out in 
PBST. 
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7.3.5. Tunable Resistive Pulse Sensing (TRPS) measurement 
Measurements were made with the Izon qNano system, (Izon Sciences, Oxford, UK) which 
incorporates the fluid cell, stretching apparatus, data recording and analysis software (Control 
Suite V2.2.2.117). Pores used to analyse SKP400 beads were designated “np400” by the 
manufacturer and are described as most suitable for detecting beads in the range 200 – 800 
nm, pores to analyse CPC800 beads,  Dynabead MyOne beads and aggregates were 
designated “np1000” by the manufacturer and have a specified range of 500 – 2000 nm. For 
np400 pores an applied stretch of 47 mm and applied voltage of 0.24 V was selected for 
np1000 pores a stretch of 47 mm was applied and a voltage of 0.08 V chosen. These 
conditions ensured that blockade events were clearly visible above the level of noise 
(<10pA); these conditions were maintained throughout the experiments so that data was 
comparable. 80µL of electrolyte buffer (PBS) was carefully pipetted into the lower fluid cell, 
taking care not to introduce bubbles. The upper fluid cell was then attached to the instrument 
and 40 µL of PBST was placed into the fluid cell to enable confirmation of a stable baseline 
and clean pore.  
To perform a calibration and attain size and concentration data a pressure of greater than 2 
cmH2O was applied so that the additional electrophoretic mobility imparted to the beads by 
the highly anionic DNA did not dominate the signal, which would lead to an overestimate in 
sample concentration
2
. The application of pressure was also advantageous to increase 
throughput and decrease analysis run time. Sample concentrations were then extracted for 
Izon Science’s (Oxford, UK) Control Suite V3.1 software. To count aggregates the raw data 
detailing the blockade magnitudes for each individual peak were extracted as a .csv file. As 
object volume is proportional to blockade magnitude the total volume of possible aggregates 
was then calculated and used to generate the expected magnitude (nA) which were used as 
bins to sort the data as described in chapter 6. To measure aggregates, an np1000 pore was 
used with a stretch of 47 mm and applied voltage of 0.08 V. 
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7.4. Results and Discussion:  
7.4.1. Confirming DNA attachment 
For this assay it was first possible to confirm that DNA had been successfully immobilised 
onto the beads. To do this the blockade frequency of the DNA modified and unmodified 
beads of the same concentration were measured under several applied voltages as displayed 
in figure 7.2. Using the relationship between particle rate and voltage as discussed in chapters 
2 and 3 it was possible to get qualitative information that the DNA was present on the beads: 
DNA loading onto the beads increases the negative surface charge density, thereby increasing 
the rate of beads traversing the pore. This technique was used to verify both the 
immobilisation of the aptamer to the SPM beads and the partial complementary sequences on 
the smaller non-SPM beads.  
As displayed in figure 7.2 for both bead sets, when DNA had been added (crosses) the rate 
(particles/minute) was higher across the range of voltages in comparison to bead which had 
not undergone EDC coupling chemistry. The gradient for beads which had undergone DNA 
conjugation was also steeper for both beads sets. It is worth noting that this effect is less 
pronounced for the Dynabead MyOne beads and that at a low voltage a difference is not 
Figure 7. 2: Plots of observed particle rate vs applied voltage (V) for beads with and without DNA. Black 
lines = CPC800 beads, red lines = dynabeads both analysed using an np1000 pore at 47 mm applied stretch. 
Circles represent results from blank beads, whilst crosses represent beads which had undergone DNA 
functionalisation.  
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clearly discernible, as suggested in chapter 3 this is likely due to the additional mass of the 
beads due to their dense iron oxide cores.  
7.4.2. Aggregate formation 
To form SPB beads loaded with their smaller particle payload, the two bead populations are 
mixed together. Initially 1×10
8
 1 µm beads/mL were mixed with 7×10
9
 800 nm beads/mL on 
a rotary wheel for 30 minutes. An alternative bead was prepared containing 2.5×10
8
 1 µm 
beads/mL and 5×10
10
 400 nm beads/mL to investigate the effect of bead size of the dispersant 
on this aptamer-based assay. A histogram of the 3 calibrated bead sets is provided in figure 
7.3.  
Figure 7. 3: Calibrated histograms displaying the diameter (nm) of DNA-modified SKP400 (I), 
CPC800 (II) and Dynabead MyOne (III) beads. 
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The calibration performed with the Izon Control Suite software assumes that the object 
moving through the pore is spherical and provides an estimation of particle diameter based on 
the blockade magnitudes of objects as they pass through the pore related to a calibration bead 
of known diameter. However, for observing aggregates an estimate of particle diameter can 
be misleading. For example, a dimer of two 400 nm beads is not the same total volume as one 
800 nm bead. Hence only the blockade magnitude (Δip) is used from this point on. The 
blockade magnitude for CPC800 and Dynabeads MyOne separately are shown in figure 7.4. 
Two methods were used to confirm the aggregation of the beads, initially their formation was 
confirmed by TRPS by an increase in blockade magnitude as displayed in figure 7.5. For the 
separate bead populations as displayed in figure 7.4 the largest recorded blockade magnitude 
was 0.675 nA whereas after mixing both particle populations together blockade magnitudes 
up to 5.125 nA were recorded. An additional observation regards the running of the qNano 
instrument which using an np1000 pore blocked far more frequently again suggesting the 
presence of large aggregate clusters.  
Figure 7. 4: Example histogram of blockade magnitude (nA) for CPC800s (black) and Dynabeads MyOne 
(blue) modified with complementary DNA or thrombin-15, respectively, prior to incubation together. 
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As the blockade magnitude is proportional to the volume of the object moving through the 
pore, it is possible to estimate the number of beads in each aggregate, it was found that the 
mean aggregate size comprised of 3×800 nm bead per dynabead or 15×400 nm beads per 
dynabead, however variance in binding and the orientation of the cluster as it traverses the 
pore add complexity
3
. 
Further confirmation that the 1 µm beads had picked up their smaller particle cargo was 
confirmed by simply counting a decrease in the number of monomers passing through the 
pore as displayed in figure 7.6. The total concentration of particles moving through the pore 
decreases as they form clusters. For the 800nm the total concentration of all the particles in 
solution had decreased to 2.6×10
9 
beads/ mL from 8×10
9 
beads/ mL, and the 400 nm particles 
the total concentration of all the particles in solution had decreased to 1.3×10
9 
beads/mL from 
5.1×10
10  
beads/ mL suggesting that aggregates have been successfully formed.  
An alternative calculation to determine the number of smaller beads per dynal bead was used 
based upon these particle concentrations. Using the particle concentrations before and after 
incubation it was possible to calculate the mean number of 400 or 800 nm beads per 
Dynabead by dividing the difference between the concentrations before and after incubation 
Figure 7. 5: Example histogram of blockade magnitude for a sample of CPC800s incubated with Dynabead 
MyOne beads. 
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by the number of Dynabeads in solution. This provided an values of 5.4×800nm beads or 
49.7×400 nm beads.  
The discrepancy between the two techniques is most likely due to a lack of resolution for the 
pore to successfully resolve the binding of individual beads, and/or the occlusion of some of 
the larger aggregates due to size.  
 
7.4.3. Thrombin addition 
Following the formation of aggregates the prepared bead mixtures were washed by magnetic 
separation four times and then incubated with varying concentrations of thrombin (thrombin 
from bovine plasma, Sigma Aldrich) or when a blank control experiment was required with 
BSA. After 30 minutes the samples were placed into a MagRack until a cluster was visible on 
the side of the vials (5 minutes) and the supernatant carefully removed to a clean sample vial 
(figure 7.1C). This was done to simplify the read out and running of the instrument as the 
less-mobile thrombin-coated beads are then removed from the measured sample leaving only 
highly electophoretically mobile DNA-coated carboxyl beads. 
Figure 7. 6: Percentage of blockades recorded as either monomers (black columns) or aggregates 
(white columns with black outlines) for 400 and 800 nm beads either with or without the addition of 
Dynabead MyOne beads which were left to incubate for 30 minutes. 
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The concentration of the non-superparamagnetic 800 nm or 400 nm beads in the blank was 
then measured via TRPS, to measure the number of dispersant beads present in solution in the 
absence of the target thrombin, displayed in figure 7.7. When BSA was added the amount of 
smaller beads in solution did not increase confirming that non-specific protein-DNA 
interactions were not able to disrupt the dsDNA and were not responsible for any increased 
particle concentration. 
As displayed in figure 7.8, for both beads increasing thrombin concentration results in an 
increased concentration of dispersed smaller non-SPM beads. By dividing the number of 
dispersed beads by the number of thrombin molecules it is possible to calculate the ratio of 
protein molecules to dynabeads and the resultant percentage of the bound non-magnetic 
beads released by each thrombin concentration, as displayed in Table 7.1 below. 
Figure 7. 7: Concentration of CPC800s following aggregate formation and magnetic separation in either PBST 
alone or in 10 µM BSA protein in PBST, n=5 and error bars represent the range of measured concentrations. 
ANOVA was performed and no significant difference was found between the BSA and PBST control groups 
(P = 0.41). 
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Thrombin 
concentration (pM) 
Ratio of thrombin 
proteins/Dynabead 
% CPC800s 
released 
% SKP400s released 
0 0 2 ± 1 1 ± 0 
0.1 0.06 38 ± 18 20 ± 5 
1 0.6 70 ± 17 55 ± 15 
5 3 100 ± 18 88 ± 14 
10 6 98 ± 20 100 ± 7 
Table 7.1: Table displaying the number of thrombin molecules in solution per dynabead bead and the average 
percentage (n=4) ± the range of the small particle payload released by the thrombin addition.  
 
As each thrombin protein binds to the aptamer it disrupts the dsDNA and causes the release 
of the smaller particle into solution. As the concentration of thrombin is well below the 
known KD of 39.1 nM, the system is never in equilibrium, nor is the surface static and due to 
the constant motion of the particles the thrombin protein is likely to dissociate from the 
aptamer and be released back into solution. As such one single thrombin molecule could 
disrupt multiple complementary DNA linkages providing an increase in sensitivity by signal 
amplification. As the number of small beads attached to the SPM beads is finite, as the 
amount of thrombin increases the curve reaches a maximum which represents all of the 
smaller beads released from the surface and is the key limiting factor in the range of this 
assay.  
Figure 7. 8: Concentration of 800 nm beads (black circles) or 400 nm beads (red circles) dispersed by thrombin with 
increasing thrombin concentration. Data shown represents the mean value obtained from four repeat experiments with 
error bars representing 1 standard deviation from the mean. 
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From figure 7.8 it is apparent that a greater concentration of 400 nm beads was ejected from 
the dynabeads in solution than the 800nm beads, although there was minimal difference in 
the blank values obtained with a mean value of 1×10
8 
beads/mL for both 400 and 800 nm 
beads from 4 repeated measurements. It was hypothesised that this is due to their smaller size 
and curvature of the 400 nm beads. More 400 nm beads would be able to fit around each 
individual dynabead with fewer binding interactions between the two, potentially leading to 
an increase in sensitivity and available range of analysis. As was observed from the shape of 
the concentration curves, using the 400 nm beads appears to increase the range of 
concentrations able to be analysed before the entire payload has been released from the SPM 
beads. 
The sensitivity of this assay relies upon the ability of TRPS to accurately count 
concentrations of the dispersed beads. To illustrate this a calibration curve was constructed 
and is displayed in figure 7.9. The concentration window measured by TRPS is dependent on 
the pore used, applied voltage, and pressure. The applied voltage was chosen to be sufficient 
to observe the particle above the level of baseline noise whilst not causing an increase in 
baseline noise. The pores used were chosen based on the manufacturer specifications and 
stated optimal size range, and a pressure of 5 cm H20 was applied to increase the accuracy 
Figure 7. 9: Calibration curve displaying the measured rate against prepared bead concentrations for triplicate 
measurements. The graph was used to calculate a limit of detection of 3.74 ×10
7
 beads/mL for the pore set up 
used to measure dispersed 400 nm beads; SKP400 pore with 47 mm applied stretch.  
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and sensitivity of the concentration calibrations. The calibration curve was conducted under 
the same TRPS conditions as the experiment itself.  
During this dispersion assay the sensitivity of thrombin detection has been improved upon by 
three orders of magnitude in comparison to the methods outlined in Chapter 4 with a signal 
measurable at a concentration of only 100 fM of thrombin. Although this proof-of-concept 
assay focussed on the measurement of thrombin protein, it would be possible to easily adapt 
the assay by simply changing the aptamer which is conjugated to the bead surface and 
creating a matching complementary sequence. In addition to improvement of sensitivity, this 
assay represents significant improvements in ease of both running and the resultant signal 
read outs.  
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7.5. Conclusion 
The detection of thrombin protein as low as 100 fM concentration has been presented. 
By using superparamagnetic beads it was possible to easily separate protein-laden 
beads, which can be difficult to analyse with pore-based technologies, enabling rapid 
analysis and improving run quality. Though thrombin was chosen to act as a proof-of-
concept demonstration of the technique, in theory this technique could be easily 
applied to any protein of interest for which there is an available aptamer or for which 
an aptamer can be developed. As such, this development represents a great 
advancement in aptamer-based TRPS assays and could pave the way for sensitive 
protein detection in a sub 5 minute assay.  
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Chapter Eight 
Concluding remarks and future work 
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8.1. Concluding remarks: 
The work presented in this thesis aims to answer the demand for new bioassays which are 
portable, simple, and rapid to move toward point-of-care-testing. Toward this overall aim, 
several methods were developed using a combination of aptamers, nano or microscale beads 
and Tunable Resistive Pulse Sensing. During the course of this PhD methods for the routine 
detection of successful DNA immobilisation on beads have been outlined, and aptamer-
coated beads have subsequently been used to successfully detect aptamer-protein interactions 
using TRPS. Several signal changes have been devised which can be used to detect proteins 
through changes in mobility, controlled aggregation and controlled dispersion of beads. 
During the course of this PhD thesis several proof-of-concept “template” assays have been 
established for use with aptamers which can be easily interchanged to measure any anaylte 
for which an aptamer is available. Several key limitations surrounding aptamer-TRPS assays 
have been outlined and described, including the use of TRPS for a multiplexed aptasensor. 
Chapter three is the first experimental chapter which focusses on the development of methods 
using TRPS to confirm the presence of DNA on the surface of beads. These are required to 
form the building blocks of all following experiments to give confidence that aptamers are 
present on the surface of beads to be used for protein detection. Results are presented for two 
methods of detection and several factors impacting upon the signal are discussed including 
DNA length, bead composition and size, and DNA hybridisation. When negatively charged 
DNA is attached to the surface of a bead, the surface charge of that bead in turn becomes 
more negative, resulting in an increase in electrophoretic mobility. The increased 
electrophoretic mobility was observed in TRPS via an increase in the frequency of blockades.  
In chapter four the detection of thrombin protein was demonstrated using TRPS as a proof-of-
concept assay. Thrombin is a haemostatic protein which has been implicated in many disease 
states and is commonly used as a start point in the development of new aptasensors. It was 
established that when thrombin is introduced to samples of aptamer-tagged beads the 
frequency of bead translocations was reduced proportionally to the concentration of 
thrombin. Additionally, using the real-time monitoring capabilities of TRPS, the interaction 
of aptamers and thrombin were observed to extract kinetic information. Furthermore, three 
different anti-thrombin aptamers each with a slight change in binding mechanism were 
scrutinised, highlighting the potential for TRPS not only as a detection platform, but also for 
the comparison of new aptamers.  
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Previous chapters have entailed the monitoring of changes in bead mobility to infer DNA or 
protein binding. However, it is also possible to engineer changes in bead size in response to 
target concentration. Though aggregation assays are well documented, current methods are 
often limited by the chosen method, for example, light scattering techniques are only able to 
provide an ‘average’ aggregate size, are unsuitable for mixed dispersions, and are easily 
biased by the presence of large outliers in a sample mixture. In chapter 5 the controlled 
aggregation of avidin coated beads in the presence of biotinylated-BSA (multiple biotins per 
molecule) is discussed. Several parameters influencing the sensitivity of the assay, such as 
magnetic separation, particle size and concentration, were addressed and several methods of 
data interpretation were presented. A problem in some aggregation assays is the onset of the 
“hook effect” in which all available binding sites are occupied leading to a reduction in 
aggregation. This is highly problematic as it could be apparent that there is no target in 
solution when in reality the concentration of target is high enough to saturate the binding sites 
available. To overcome this effect the addition of extra beads to the reaction mixture prior to 
analysis was tested to extend the range of analysis for the assay. This chapter identifies 
several key factors in tailoring an aggregation assay and provides examples of data 
interpretation for use as a template for future assays. 
In chapter six the use of TRPS to detect aptamer-ligand interaction on the surface of beads 
was expanded to provide a template for multiplexed detection building upon the foundations 
set in the fourth chapter. The growth factors vascular endothelial growth factor (VEGF) and 
platelet derived growth factor (PDGF) are both implicated in various disease processes and 
are potentially very valuable biomarkers of disorders where haemostatic control and 
angiogenesis are implicated. Taking advantage of the particle-by-particle analysis provided 
by TRPS, beads of different sizes were used to act as a label with 120 nm bead typically used 
for VEGF detection and 300 nm beads used for PDGF detection in the same sample, this 
enabled data sorting based on blockade magnitude and for the particle rates of the two 
individual populations to be separated. Additionally factors such as pH and protein isoelectric 
point are discussed with regards to tailoring the resultant signal upon protein binding. This 
improved upon the initial proof-of-concept assay by not only expanding the range of analytes 
and including multiplexing capability, but also by allowing for the generation of a positive 
signal in response to protein binding, a vast improvement upon the initial diminution of 
signal observed for thrombin in chapter four.   
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Chapter seven presents the controlled aggregation and dispersion of double stranded 
DNA (dsDNA) linked aggregate in the presence of the protein target thrombin. The basis 
of this aptasensor is the controlled dispersion of nanoparticles in the presence of the 
target analyte, which is measured via Tunable Resistive Pulse Sensing (TRPS). Each 
analyte triggers the release of multiple particles, and this amplified signal allows the 
detection of the analyte orders of magnitude lower than previous methods. To do this, 
1 µm superparamagnetic beads (SPBs) were coated with anti-Thrombin aptamers and 
incubated with nonmagnetic beads coated with a partially complementary 
oligonucleotide. The aggregates were monitored by TRPS by both an increase in 
volume and a decrease in blockade frequency. Following the addition of the target 
protein the aptamer undergoes a conformational change, dissociating from the 
complementary oligonucleotides and causing the SPM beads to release their payload. 
The number of released beads increases with the concentration of the protein. This 
method was sensitive enough to detect down to 100 fM concentrations of thrombin, 
three orders of magnitude lower than previous reports using TRPS in chapter four.  
The experiments detailed in this thesis demonstrate that TRPS can be successfully 
utilised to measure the attachment of aptamer to nano and micorscale beads. 
Following on from this, several assays were performed using TRPS to analyse 
aptamer-coated particles interacting with different target proteins with relatively 
simple rapid measurements in alignment with the overall aims of this thesis to explore 
TRPS as a measurement tool for observing the interaction of clinically relevant 
proteins and their aptamers. 
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8.2. Future work: 
The work in this thesis has provided several proof-of-concept bioassays for use with TRPS, 
however, before any of these can be used outside of the laboratory there is much work to be 
done to extend this research from proof-of-concept to a real diagnostic technology.  
Perhaps one of the most important considerations in the expansion of these assay formats is 
the standardisation of materials and procedures. During the course of this PhD it has become 
apparent that batch to batch variation in concentration of commercially provided beads is at 
current significant. While in these experiments this did not pose a significant issue as each 
batch could be independently calibrated and adjusted, in a clinical environment it would be 
far preferable to reduce the number of preparation steps and measurements by ensuring that 
all materials were consistent. Additional to this, it would be necessary to quantify the shelf-
life of the aptamer tagged beads if they were to be incorporated into clinical measurements. 
To further simplify the assay and measurement outlined in this thesis one particular avenue to 
explore may be a dispersion assay which occurs from a surface rather that from large 
aggregates; this would further simplify an assay and allow for greater control as well as 
standardisation. This could be done via a lateral flow assay in which a glass slide is coated 
with aptamer and beads coated with a complementary sequence are immobilised onto the 
surface. Alternatively creating a ‘dipstick’ coated with aptamers and complement-bound 
beads which could simply be dropped into a sample solution and removed after a set period 
may be another viable option for assay improvement. Additionally, a dispersion assay could 
in theory be integrated with the multiplexed assay discussed in chapter six to enable rapid 
screening of multiple proteins and increase diagnostic potential.  
The generic assay formats outlined in this thesis could also in theory be easily expanded to 
analyse almost any target for which there is an aptamer available and as a wider variety of 
proteins are monitored in these assays this will enable a greater understanding of the impact 
of structural differences in protein on the assay signal and enable greater control. 
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